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Abstract 
There is increasing evidence that neuro-inflammation drives disease progression in many 
neurodegenerative conditions. Amyotrophic lateral sclerosis (ALS) is a debilitating, late onset 
neurodegenerative disorder that is characterized by the progressive death of upper and α-motor 
neurons within the central nervous system (CNS). Components of the innate immune complement 
system have been implicated in the pathogenesis of ALS. Within the complement signalling cascade 
C3a and C5a are regarded as potent inflammatory and immunomodulatory peptides with various 
biological functions. In the CNS their functions include chemotaxis and proliferation of microglia 
and astrocytes; generation of superoxide radicals; and induction of pro-inflammatory cytokine 
synthesis – all thought to be achieved via their main signalling receptors C3aR and CD88. Some of 
these functions have been observed in neurodegenerative disease, suggesting that these complement 
factors may play a role in ALS pathogenesis. However a comprehensive examination of 
complement expression and function of C3aR and CD88 in this disease has not been performed.  
 
The initial aim of this thesis was to determine the expression of complement components (C1qB, 
C4, factor B, C3/C3b, C5, CD88 and C3aR) and regulators (CD55 and CD59a) in the lumbar spinal 
cord of the transgenic hSOD1
G93A
 mouse model of ALS. This was conducted during distinct disease 
stages, which were defined in this thesis. We found several early complement factors increased as 
disease progressed, whilst complement regulators decreased; suggesting overall increased 
complement activation through the classical or alternative pathways in hSOD1
G93A
 mice. CD88 and 
C3aR was also increased during disease progression, with immunolocalization demonstrating 
expression on motor neurons and increasing expression of CD88 on microglia and increasing 
expression of C3aR on astrocytes surrounding the regions of motor neuron death.  
 
Our previous studies have demonstrated that hSOD1
G93A 
rats treated with the selective CD88 
antagonist PMX205 had reduced gliosis and improvements in behavioural deficits, consistent with 
reduced neuropathology; suggesting CD88 has a pathogenic function in ALS. However, the 
contribution of C3aR to disease progression in ALS is still unknown. This thesis therefore next 
aimed to confirm the function of CD88, and determine the function of C3aR, in the disease 
progression of ALS in hSOD1
G93A
 mice. The function of CD88 signalling was investigated using 
two different approaches (pharmacological and genetic). Inhibition of CD88 using PMX205 
(pharmacological approach) or hSOD1
G93A
 mice lacking CD88 (genetic approach) showed similarly 
extended survival when compared to vehicle and hSOD1
G93A
 mice. There was also a reduction in 
microglia, monocytes and cytokines (TNFα and IL-1β) transcripts in the spinal cord at the end-stage 
of disease. Taken together these results indicate that inhibition of CD88 significantly attenuates 
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disease progression potentially by reducing microglia/monocyte activation and generation of pro-
inflammatory cytokines, which all have an important role in motor neuron death that contributes to 
pathology in the hSOD1
G93A
 mice. 
 
Due to a lack of a selective and brain permeable C3aR antagonist, the function of C3aR signalling 
was investigated by using hSOD1
G93A
 mice lacking C3aR (hSOD1
G93A
 x C3aR
-/-
) and comparing 
survival with hSOD1
G93A
 mice. By contrast with CD88, hSOD1
G93A
 x C3aR
-/-
 mice showed 
significantly reduced survival relative to hSOD1
G93A
 mice and showed worsened behavioural 
deficits compared to hSOD1
G93A
 mice. There were also increased astrocyte and microglia 
transcripts but no change in cytokines (TNFα and IL-1β) transcript levels in the spinal cord at end-
stage of disease. Taken together these results indicate that inhibition of C3aR significantly 
exacerbates disease progression potentially by increasing astrocytes and microglia activation, 
independent to inflammatory cytokines. This finding also opens a new window of opportunity to 
target C3a-C3aR signalling in astrocytes using selective agonists, to potentially slow ALS disease 
progression.  
 
In summary, these results indicate that there is dysregulation of the complement system in the 
disease progression in a widely used ALS transgenic model. Complement peptides C3a and C5a 
generated during complement activation and their receptors C3aR and CD88 have two opposing 
roles in the progression of ALS in the hSOD1
G93A
 mouse. Hence therapeutic modulation of 
complement activation in ALS should be targeted towards downstream C5a inhibition, in order to 
avoid blocking any endogenous protective effects of upstream factors such as C3a in ALS 
progression.  
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PIP3 - Phosphoinositol trisphosphate  
PKC - Protein kinase C 
PLC β2 - Phospholipase β2 
PS - Pre-symptomatic  
SOD1 – Superoxide Dismutase 1 
TBS-T - Tris buffered solution- 0.1% Tween 20  
TNFα - Tumour necrosis factor α  
WT - Wild-type  
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CHAPTER 1 
“General Introduction” 
* Part of this chapter was published as a book chapter in Amyotrophic Lateral Sclerosis - 
John D. Lee, Jia Y. Lee, Stephen M. Taylor, Peter G. Noakes and Trent M. Woodruff: Innate 
Immunity in ALS. In Amyotrophic Lateral Sclerosis. Edited by Maurer MH. InTech; 2012: 393-412 
 
1. INTRODUCTION 
Long term activation of complement has been implicated in numerous neurodegenerative diseases 
including motor neuron disease (MND), Huntington’s disease (HD), Alzheimer’s disease (AD), and 
Parkinson’s disease (Woodruff et al., 2008a, Woodruff et al., 2006, Fonseca et al., 2009, Loeffler et 
al., 2006). Within the complement signalling cascade C3a and C5a are regarded as potent 
inflammatory peptides with various biological functions. In the central nervous system (CNS) their 
functions include chemotaxis and proliferation of microglia and astrocytes; generation of 
superoxide radicals; and induction of pro-inflammatory cytokine synthesis – all thought to be 
achieved via their main signalling receptors C3aR and CD88 respectively (Wetsel, 1995a, Wetsel, 
1995b, Gerard and Gerard, 1994, Crass et al., 1996, Ember and Hugli, 1997). Some of these 
functions have been observed in the above mentioned neurodegenerative diseases, suggesting that 
complement factors may play a role in the pathogenesis of these diseases. 
 
1.1 Motor Neuron Disease 
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is the most common 
form of MND. It is a debilitating, late onset neurodegenerative disorder that is characterized by the 
progressive death of upper and α-motor neurons within the CNS (Bruijn et al., 2004). This results in 
symptoms of muscle weakness and atrophy of skeletal muscles, leading to paralysis and eventual 
death due to failure of respiratory muscles (Cozzolino et al., 2008). ALS has a prevalence of 
approximately 1~2 per 100,000 worldwide with males being more susceptible than females (1.3 ~ 
1.6: 1) (Strong, 2003, Woodruff et al., 2008b, Worms, 2001). The majority of ALS cases (~90%) 
are thought to be sporadic with unknown aetiology and no robust environmental risk factors, with 
the remaining 10% being familial. Of this 10%, approximately 20% have been linked to dominant 
mis-sense point mutations in the Copper/Zinc superoxide dismutase 1 (SOD1) gene, which results 
in a gain of unidentified deleterious properties (Rosen, 1993). Interestingly, the two aetiologies of 
ALS (i.e. sporadic and familial) are indistinguishable on the basis of their clinical and pathological 
features, including progressive muscle weakness, atrophy and spasticity, each of which reflects the 
degeneration and death of upper and α-motor neurons (Boillee et al., 2006). The mechanisms 
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leading to ALS are still unclear but theories have suggested that glutamate excitoxicity, oxidative 
stress, protein aggregation, mitochondrial dysfunction, cytoskeletal abnormalities and neuro-
inflammation are all likely to play a role (Turner et al., 2013). Research into both the aetiology and 
mechanism of neurodegeneration may be helpful to identify potential therapeutic targets and 
treatments for ALS.  
 
1.2 Innate immunity in neurodegenerative disease 
Innate immunity is an evolutionary ancient system that provides the host with immediately 
available defence mechanisms. It is a rapid and coordinated cascade of reactions by host cells to 
protect them against foreign pathogens and insults (Akira et al., 2001, Nguyen et al., 2004). Until 
recently, the CNS was considered to be immunologically privileged because of its perceived 
inability to mount an immune response and process antigens. Recent studies have revealed that 
immune surveillance and differentiation between self and non-self does take place in the CNS, 
where glial cells, including microglia, astrocytes and oligodendrocytes, act as CNS immune effector 
cells (Hanisch et al., 2008, Lehnardt, 2010, Ricklin et al., 2010).  
 
The role of innate immune system in the CNS is mainly to provide protection to neurons from 
foreign pathogens and injurious stimuli, and to maintain CNS homeostasis. It is also required for 
tissue modelling during development and following injury (Benard et al., 2008, Stevens et al., 2007, 
Mastellos et al., 2005, Rahpeymai et al., 2006). However sustained chronic inflammation can be 
harmful for neuronal integrity and may result in cellular dysfunction, which may drive 
neurodegeneration. There is increasing evidence that suggests an involvement of the innate immune 
system in the development of neuro-inflammation that underpins the progression of many 
neurodegenerative diseases including ALS. One of the major constituents of innate immune system 
is the complement cascade, which is the focus of this thesis, and is described in detail below. 
 
1.3 The complement system in the CNS 
The complement system participates in the recognition, trafficking and elimination of pathogens 
and unwanted host materials. It is an enzymatic cascade consisting of more than 30 plasma proteins 
and glycoproteins, and either soluble or membrane-bound receptors (Guo and Ward, 2005). 
Complement activation participates in host defence against pathogens primarily by cytotoxic and 
cytolytic activity through triggering formation of the membrane attack complex (MAC or C5b-9) 
on the target cell membrane (van Beek et al., 2003). It is activated via three canonical pathways: the 
classical, alternative, and lectin pathways; however importantly, it can also be activated by a fourth, 
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extrinsic protease pathway that does not require upstream complement activation (summarized in 
Figure 1.1) (Huber-Lang et al., 2006, Thoman et al., 1984).  
 
 
  
 
 
Figure 1.1: The Complement Cascade. Complement is part of the innate immune system and can 
be activated via four different pathways: the classical pathway, an antigen-antibody complex; the 
alternative pathway, activated by bacteria and foreign surfaces; the lectin pathway activated by 
mannose binding lectin; and recently discovered extrinsic protease pathway involving direct 
cleavage of C3 and C5. Each pathway converges at C3 and leads to a common terminal point 
which involves the formation of the cytolytic membrane attack complex (MAC) leading to cell lysis. 
Formation of pro-inflammatory peptides C3a and C5a induces glial chemotaxis, proliferation, 
generation of superoxide radicals and release of inflammatory mediators. C3b and iC3b facilitates 
phagocytosis by opsonising foreign pathogens. 
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The classical pathway is primarily activated in response to the recognition molecule C1q binding to 
antigen-antibody complexes such as immunoglobins (IgG and IgM) and pentraxins (such as C-
reactive protein) bound to their targets (Ricklin et al., 2010, Woodruff et al., 2010). C1q may also 
bind directly to pathogen surfaces and to non-pathogen surfaces such as beta-amyloid and 
liposomes (Jiang et al., 1994, Marjan et al., 1994). The alternative pathway is activated by foreign 
surfaces that amplify the slow spontaneous hydrolysis of C3 which leads to the formation of C3 
convertases (Pangburn et al., 1981, Ricklin et al., 2010). By contrast, the lectin pathway is initiated 
following the binding of mannose-binding lectin to carbohydrate groups on the surfaces of some 
pathogens (Woodruff et al., 2010). The activation of each of these pathways results in assembly of 
C3 and C5 convertase enzymes, which cleave their respective inactive complement factors C3 and 
C5 into their active fragments C3a, C3b, C5a and C5b. This leads to the formation of MAC through 
the non- enzymatic assembly of C5b with complement factors C6-C9, forming C5b-9 on the cell 
membrane, which creates a transmembrane pore, ultimately leading to cell lysis (Podack et al., 
1982). 
 
A recently identified fourth extrinsic pathway involves direct cleavage of C3 and C5 into C3a/C3b 
and C5a/C5b by proteolytic enzymes (serine proteases) such as kallikrein, thrombin and cell-
derived proteases (Huber-Lang et al., 2002, Huber-Lang et al., 2006). As a result, synthesis of C5 
by local inflammatory cells can produce C5a via cleavage of C5 with cell derived proteases, even 
when devoid of the complement cascade precursor, C3 (Huber-Lang et al., 2006). This pathway 
may provide a source of complement activation factors in the absence of upstream complement 
activation, and in a local tissue environment such as the CNS (Woodruff et al., 2010). 
 
The primary function of complement activation is to provide a rapid response to infection and 
injury by initiating the production of opsonins C1q and C3b to opsonise pathogens, the production 
of the pro-inflammatory peptides C3a and C5a to recruit immune and inflammatory cells through 
ligand-receptor interactions with their corresponding receptors, C3aR and CD88, and the formation 
of cytolytic MAC, which ultimately leads to the destruction of invading organisms by cell 
apoptosis/necrosis (Liszewski et al., 1996). 
 
Although the CNS does not receive the same composition of circulating complement factors 
synthesised in the liver by hepatocytes, due to the blood brain barrier (BBB), many studies have 
revealed that the CNS contains key components of complement cascade, where they are expressed 
by astrocytes, microglia, oligodendrocytes and neurons (Barnum, 1995, Gasque et al., 1997, Nataf 
et al., 2001, O'Barr et al., 2001, Stephan et al., 2012). Similar to the peripheral system, the role of 
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complement activation within the CNS is thought to primarily protect the neurons from foreign 
pathogens through activation of inflammatory and immune cascades by surrounding glial cells. In 
addition to their immune surveillance functions, recent studies have shown that complement 
molecules also have a role in adaptive immune response, nervous system development, regeneration 
and regulating CNS homeostasis by clearing cellular debris and also eliminating excess synapses 
(i.e. synaptic pruning) (Stevens et al., 2007, Stephan et al., 2012). Intriguingly, synaptic loss is not 
only a feature of neural development but is also a key pathological feature of neurodegenerative 
diseases (Schafer and Stevens, 2010, Woodruff et al., 2010). Hence it has been proposed that 
complement has multiple central roles in the CNS other than its canonical functions associated with 
host defence (Benard et al., 2008, Rahpeymai et al., 2006, Stevens et al., 2007, Stephan et al., 
2012). Therefore dysregulation or imbalance of the complement system in the CNS can be harmful 
to the neurons and may lead to, or contribute to, neurodegenerative diseases including ALS. 
 
1.4 Complement peptide C3a 
One aspect of complement activation that is particular importance in the inflammatory response is 
the generation of biologically active peptides C3a and C5a. C3a is one of the complement peptides 
that are cleaved from C3 during complement activation. C3a is a 77-amino acid polypeptide that 
binds to and exerts its major effects through its high affinity receptor, the C3aR (Crass et al., 1996, 
Ember and Hugli, 1997). C3aR is a member of the rhodopsin family of seven transmembrane G-
protein coupled receptors with smaller N-terminal domain and a greatly enlarged second 
extracellular domain (Figure 1.2) (Klos et al., 2013). Following the binding of C3a to C3aR, the 
primary signalling mechanism activated is through the pertussis toxin-sensitive G-protein Gαi and 
also through pertussis toxin-insensitive G-protein Gα12/13 and Gα16 (Langkabel et al., 1999, Crass et 
al., 1996, Klos et al., 2013, Li et al., 2008). Cellular activation of C3aR involves intracellular 
calcium mobilisation and activation of different signalling pathways including phosphatidylinositol-
3-kinase/Akt (PI3Kγ), phospholipase C, mitogen-activated protein kinase (MAPK)/extracellular 
signal-related kinase 1/2 (ERK1/2), protein kinase C (PKC), nuclear factor - κB (NF- κB) and 
inhibition of MAPK/p38 and adenylate cyclase (summarised in Figure 1.3) (Klos et al., 1992, Li et 
al., 2008, Sayah et al., 2003, Gupta et al., 2012, Vibhuti et al., 2011). It is widely expressed on a 
variety of cells including glial cells, endothelial cells and neurons (Nataf et al., 1999), and its 
activation is known to have pro-inflammatory functions such as chemotaxis, degranulation, 
generation of cytokine and chemokine, superoxide production, smooth muscle contraction and cell 
apoptosis (Ember and Hugli, 1997, Gasque et al., 2002, Jacob et al., 2010, Legler et al., 1996, 
Kretzschmar et al., 1993, Sayah et al., 1999, Jauneau et al., 2003, Elsner et al., 1994a, Elsner et al., 
1994b, Petering et al., 2000).  
6 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Complement peptide C5a and C3a receptors CD88 and C3aR. Both receptors have 
overall sequence identity of 37%. Sequence and domain structures are shown for CD88 and C3aR. 
Glycosylation sites are indicated by the black ovals. Phosphorylation sites in intracellular domains 
and tyrosine sulfation sites in extracellular domains are indicated by grey circles. Unlike CD88, 
C3aR consists of smaller N-terminal domain and a greatly enlarged second extracellular domain. 
Adapted from (Klos et al., 2013).  
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Figure 1.3: Schematic view showing the main signaling pathways initiated by C3aR and CD88 
activation. Cellular activation of C3aR and CD88 involves intracellular calcium mobilisation. 
Upon binding of C3a and C5a, receptor undergoes conformational change that enables 
dissociation of βγ complex from α subunit. Following its dissociation from α subunit, βγ complex of 
G-protein activates Phospholipase β2 (PLC β2) and PI3Kγ. PI3Kγ converts membrane 
phosphoinositol-4, 5 bisphophate (PIP2) into phosphoinositol trisphosphate (PIP3), which activates 
PKC. PLC β2 hydrolyses PIP2 into diacylglycerol (DAG) and inositol trisphosphate (IP3). IP3 
causes the release of calcium from the intracellular calcium stores. Interplay between calcium and 
DAG activates the PKC. PKC is involved in the superoxide production by regulating nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase. Enhancing the activity of Src-like tyrosine 
kinases phophorylate docking proteins such as Shc adaptor protein, leads to the activation of Ras-
Raf-MAPK-ERK pathway, which is involved in chemotaxis and superoxide production. Lastly, 
activation of low molecular weight G-proteins of the Rho family (Rho, Rac and Cdc42) via GEFs 
activation regulate many leukocyte functions, including adhesion to endothelial cells, chemotaxis 
and superoxide generation. Adapted from (Rabiet et al., 2007). 
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1.5 Role of C3a in CNS diseases 
Several studies have provided evidence indicating a pro-inflammatory role of C3a-C3aR signalling 
in the pathogenesis of CNS diseases including experimental lupus, traumatic brain injury and 
experimental autoimmune encephalomyelitis (EAE) (Jacob et al., 2010, Li et al., 2013, Wang et al., 
2010, Boos et al., 2004). Specifically, they showed a significant up-regulation of C3aR and 
demonstrated that inhibiting C3aR using C3aR antagonist and decay accelerating factor (DAF) 
reduced pro-inflammatory cytokine release such as tumour  necrosis factor α (TNFα) and 
interleukin -1β (IL-1β), astrogliosis, phosphorylated tau and improved BBB integrity in 
experimental lupus and traumatic brain injury (Jacob et al., 2010, Li et al., 2013). Ablation of C3aR 
in the brain attenuated EAE, whereas overexpression of C3a in the brain exacerbated EAE (Boos et 
al., 2004). Ultimately inhibition of C3aR in experimental lupus and traumatic brain injury lead to 
reduction in neuronal cell death while C3a-C3aR signalling developed more severe EAE, 
suggesting that C3a-C3aR has a pathogenic role in these CNS diseases. 
 
By contrast, many studies have also demonstrated an anti-inflammatory role of C3a-C3aR 
signalling. C3a has been found to suppress the secretion of lipopolysaccharide (LPS)-induced pro-
inflammatory cytokine TNF-α, IL-1β and interleukin-6 from peripheral blood mononuclear cells 
and modulate production of anti-inflammatory hormones (Fischer and Hugli, 1997, Takabayashi et 
al., 1998, Takabayashi et al., 1996, Francis et al., 2003). Mice lacking C3aR are more sensitive to 
LPS-induced lethality with increased IL-1β synthesis, suggesting that C3a-C3aR signalling plays a 
protective role by modulating pro-inflammatory cytokine synthesis (Kildsgaard et al., 2000). 
Furthermore it was also found that there was increased resistance to endotoxin induced lethality in 
mice that overexpress C3a in astrocytes (Boos et al., 2005). In support of these findings, a recent 
report also revealed marked neuroprotective properties for both C3a overexpression in the brain and 
administration of exogenous C3a peptide following neonatal ischemic brain injury (Jarlestedt et al., 
2013). These combined studies suggest that C3a may also have anti-inflammatory functions, which 
could alleviate the progression of neurodegenerative diseases such as ALS. 
 
1.6 Complement peptide C5a 
C5a is considered to be the most potent inflammatory molecule generated upon complement 
activation and exhibits a broad range of functions. C5a is a 74-amino acid polypeptide that exerts its 
effect through two high affinity receptors, the classical C5a receptor (CD88), and the C5a-like 
receptor 2 (C5L2/GPR77). CD88 is a member of the rhodopsin family of seven transmembrane 
domain receptors coupled to the hetero-metric G proteins of the Gi subtype: pertussis toxin-
sensitive Gαi2, Gαi3 or pertussis toxin-insensitive Gα16 (Amatruda et al., 1993, Johswich and Klos, 
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2007, Rollins et al., 1991). Cellular activation of CD88 involves intracellular calcium mobilization 
and activation of different signalling pathways including PI3Kγ (Perianayagam et al., 2002), Ras/B-
Raf/MAPK/ERK (Buhl et al., 1994), phospholipase A2, phospholipase D (Cockcroft, 1992, 
Mullmann et al., 1990), PKC (Buhl et al., 1994), p21-activated kinases, Rac GTPases (Huang et al., 
1998), signal transducers and activators of transcription, sphingosine kinase (Melendez and 
Ibrahim, 2004) and NF-κB (Kastl et al., 2006)(summarised in Figure 1.3). It is widely expressed on 
variety of cells and tissues, and its activation is known to have pro-inflammatory functions such as 
chemotaxis, degranulation, superoxide production, and release of proteases, eicosanoids, cytokine 
and chemokine from inflammatory cells (Gomez-Cambronero et al., 2007, Melendez and Ibrahim, 
2004, Torres and Forman, 1999, Tsai et al., 2004). 
 
1.7 Role of C5a in CNS diseases 
Despite the availability of studies demonstrating potential neuroprotective activities of C5a (Osaka 
et al., 1999, Mukherjee and Pasinetti, 2001, Mukherjee et al., 2008, O'Barr et al., 2001), the overall 
body of evidence accumulated to date suggest that C5a induced CD88 activation plays a pathogenic 
role in CNS diseases. In particular, CD88 activation seemed to be the driver of CNS pathology in 
numerous neurodegenerative diseases including AD, HD and ALS (Farkas et al., 2003, Fonseca et 
al., 2009, Fonseca et al., 2013, Singhrao et al., 1999, Woodruff et al., 2006, Woodruff et al., 2008a, 
Humayun et al., 2009). This was demonstrated by increased CD88 expression in human tissue and 
protection in animal models using a specific CD88 antagonist PMX205 (Fonseca et al., 2009, 
Woodruff et al., 2006, Woodruff et al., 2008a).  
 
Specifically, they showed increased CD88 immunoreactivity concentrated around the β-amyloid 
plaque, which is a prominent feature of AD (Fonseca et al., 2013). In support of this pathogenic role 
for C5a in AD, previous study have shown that oral treatment with the CD88 antagonist PMX205 
significantly attenuated AD-like pathology after 12 weeks of treatment in two distinct mouse 
models of AD. The reduction in pathology was correlative with improvements in contextual 
memory (Fonseca et al., 2009). CD88 is also up-regulated in the striatum of HD patients when 
compared with tissue from non-HD individuals (Singhrao et al., 1999). This is specifically on 
neurons and proliferating glia in the degenerating regions of HD brains, suggesting an involvement 
of CD88 activation in the progression of this disease. Previous study also showed that pre- or post-
treatment of 3-nitropropionic acid induced striatal neurodegeneration in rats with CD88 antagonist 
PMX205 significantly reduced striatal lesion size, apoptosis, neutrophil infiltration, astrocyte 
proliferation and improved neurological deficits, indicating a pathogenic role for C5a in this disease 
model (Woodruff et al., 2006). Similar to AD and HD, there is significant up-regulation of CD88 on 
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proliferating astrocytes in the vicinity of degenerating motor neurons in the lumbar spinal cord of 
hSOD1
G93A
 rats (Woodruff et al., 2008a). Furthermore, CD88 antagonist PMX205 treatment in 
hSOD1
G93A
 rats reduced motor deficits and extended survival, indicating a pathogenic role for 
CD88 in ALS (Woodruff et al., 2008a). Taken together, these combined studies suggest that C5a 
has an important role in neuronal death and its activation could exacerbate the disease progression 
of neurodegenerative diseases such as ALS. 
 
1.8 Clinical evidence of complement involvement in ALS 
Several studies have been conducted on ALS patients in an attempt to identify whether complement 
components are up-regulated in disease progression (Table 1.1). It has been proposed that the 
classical complement pathway is involved in the pathophysiology of ALS, as studies have shown 
that activation fragments of complement components C3 and C4 are increased in the serum, 
cerebrospinal fluid (CSF), and neurological tissue (including spinal cord and motor cortex) of ALS 
patients (Annunziata and Volpi, 1985, Apostolski et al., 1991, Goldknopf et al., 2006, Kawamata et 
al., 1992, Trbojevic-Cepe et al., 1998). The first of these studies examined C3 immunofluorescence 
in spinal cord and motor cortex of 16 ALS patients and demonstrated significant C3 deposition, 
which appeared to be on astrocyte-like cells with no apparent neuronal staining (Donnenfeld et al., 
1984). Subsequent studies measured C3c, C4, C1 inactivator and C3 activator fractions in the serum 
and CSF of 13 ALS patients but only detected increased levels of C3c in the CSF of ALS patients 
compared to normal individuals (Annunziata and Volpi, 1985). Furthermore Apopstolski and 
colleagues (1991) measured serum C4, C3 and Factor B levels in 33 ALS patients and found an 
increase in C4 levels when compared to normal individuals (Apostolski et al., 1991). Increased 
clusters of C3d and C4d coated fibers on oligodendroglia and degenerating neurites in spinal cord 
and motor cortex was also found in 8 ALS patients compared to 5 normal individuals (Kawamata et 
al., 1992). Two separate studies also investigated C1q, C4d and C4 levels in the serum and CSF of 
ALS patients and found C4d levels significantly increased in 15 ALS patients which also correlated 
with disease severity (Tsuboi and Yamada, 1994); another study also detected up-regulation of C4 
in ALS patients (Trbojevic-Cepe et al., 1998). Studies by Grewal and colleagues (1999) and Jiang 
and colleagues (2005) have identified increased mRNA of upstream classical pathway complement 
components (C1q and C2) in the spinal cord of ALS patients (Grewal et al., 1999, Jiang et al., 
2005). Recently, Sta and colleagues (2011) have found increased levels of C1q, C3c, C3d and C5b-
9 in the spinal cord and motor cortex of ALS patients compared to normal individuals (Sta et al., 
2011). The expression of these complement components was observed in glial cells rather than 
neurons (Sta et al., 2011). Lastly, complement component C3 was also found to be up-regulated in 
the CSF of 71 ALS patients when compared to 40 normal individuals (Ganesalingam et al., 2011). 
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These findings of up-regulated complement components and activation fragments, predominantly 
composing the classical pathway, in the serum, CSF, and neurological tissue in ALS patients 
strongly suggest that the classical complement pathway may be involved in the progression of 
disease in ALS. However it is currently unknown where these complement factors originate, and 
what initiates their activation. Complement factors can be produced by various cells within the CNS 
suggesting local production in response to disturbance in CNS homeostasis due to immunoglobulin 
deposits and auto-antibodies in the CNS of ALS patients (Donnenfeld et al., 1984, Niebroj-Dobosz 
et al., 2006). Also the circulation could be a source of these complement factors as there is BBB 
breakdown in the end stages of ALS (Apostolski et al., 1991). Overall, evidence from these clinical 
studies helps us to propose that complement system activation occurs in ALS patients, and may 
play a role in the disease pathology. This is also supported by evidence of studies showing 
involvement of complement factors in animal models of ALS. 
 
Table 1.1 Clinical evidence of complement activation in ALS patients 
 
Complement 
factors 
mRNA/Protein Sample Methods 
C3 Protein Spinal Cord, 
Motor cortex 
Immunofluorescence 
C3c Protein Serum, CSF Single radial immuno-diffusion 
C4 Protein Serum Single radial immuno-diffusion 
C3d, C4d Protein Spinal Cord, 
Motor cortex 
Immunohistochemistry 
C4d Protein CSF Sandwich ELISA 
C4 Protein CSF Laser nephelometry 
C1q mRNA Spinal Cord, 
Motor cortex 
Northern blot, In situ 
hybridization 
C2 mRNA Spinal Cord Microarray 
C3c, C3dg, Factor 
H 
Protein Serum 2D gel electrophoresis 
C1q, C3c, C3d, 
C5b-9 
mRNA/Protein Spinal Cord, 
Motor cortex 
qPCR, immunohistochemistry 
C3 Protein CSF Sandwich ELISA 
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1.9 Experimental evidence of complement involvement in ALS 
Many studies in animal models of ALS have shown the involvement of the complement system 
during disease progression, supporting findings in ALS patients (Table 1.2). Although the SOD1 
gene mutation only accounts for 2% of total ALS cases, mouse models carrying over-expression of 
mutant human SOD1 enzyme are widely used, as it leads to progressive symptoms, which are very 
similar to the human condition.  
 
The first study to demonstrate experimentally the involvement of complement factors in a SOD1 
transgenic mouse model was performed by Perrin and colleagues in 2005. They isolated ventral 
motor neurons from the lumbar spinal cord of hSOD1
G93A
 transgenic mouse using laser-capture 
micro-dissection and then using microarray analysis they detected increased levels of all 
subcomponents of C1q in these mice at early symptomatic and end stage when compared to motor 
neurons from wild-type (WT) mice (~5 and ~8 fold respectively) (Perrin et al., 2005). 
 
Subsequent studies in two distinct hSOD1 transgenic mouse models also used laser-capture micro-
dissection to isolate lumbar motor neurons from hSOD1
G37R
 and hSOD1
G85R
 transgenic mice which 
showed up-regulation of genes for all three C1q subcomponents when compared to hSOD1
WT
 mice 
2 months prior to clinical onset (Postnatal (P) 105 days) (Lobsiger et al., 2007). In addition, this 
group demonstrated that the complement regulatory molecule, DAF also decreased at this time 
point (Lobsiger et al., 2007). Furthermore they showed that C1q protein was expressed by motor 
neurons using immunohistochemistry on spinal cord sections of both hSOD1
G37R
 and hSOD1
G85R
 
transgenic mice but absent in the age-matched control mice (Lobsiger et al., 2007). 
 
A separate group also used laser-capture micro-dissection to isolate the lumbar motor neurons from 
SOD1
G93A
 transgenic mice. Using microarray analysis and real time quantitative PCR, they showed 
there were increased levels of C1q (subcomponent B) and C4 mRNA at disease onset (P90) and 
late-stage disease (P120) (~7 and ~8 fold respectively) (Ferraiuolo et al., 2007). A similar study also 
used microarray analysis in a separate hSOD1 transgenic mouse model using whole lumbar spinal 
cord homogenate (Fukada et al., 2007). This study used hSOD1
L126delTT
 transgenic mice and showed 
elevated levels of C1q (subcomponent B) mRNA in post-symptomatic (P154) mice compared to 
WT mice. A very recent study has shown increased levels of C1q in the neuromuscular junction of 
hSOD1
G93A
 transgenic mice compared to WT mice (Heurich et al., 2011). 
 
By contrast to the above studies, which indicates a role for the classical complement pathway in the 
progression of pathology of the hSOD1 transgenic mouse, recent studies have demonstrated that 
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when hSOD1
 
transgenic mice were bred onto a background deficient in complement C1q, C3 and 
C4, there was no difference in the onset of motor symptoms and survival when compared to hSOD1 
transgenic mice (Chiu et al., 2009, Lobsiger et al., 2013). These studies indicate that blocking 
upstream complement activation pathways does not alter the disease course in hSOD1 transgenic 
mice. It is possible instead, that downstream complement factors, potentially generated by the 
fourth “extrinsic pathway”, may play a role in immune activation and macrophage recruitment in 
these mice. 
 
To further validate the involvement of downstream components of the complement cascade in the 
disease progression of ALS, up-regulation of C5a receptor CD88 mRNA and protein was observed 
in mice deficient in the low molecular weight neurofilament (NFL) subunit protein, a mouse model 
of motor neuron degeneration in which neurofilament aggregates in a similar fashion to that in ALS 
patients (Humayun et al., 2009). This study showed that there was a 4 and 3 fold increase in CD88 
mRNA expression level at 2 and 3 months respectively, a time which is early in the disease process 
(Humayun et al., 2009). There was also an increased immunoreactivity of CD88 in motor neurons 
of NFL deficient mice when compared to WT mice at 3, 4 and 5 months. Our own findings also 
support a pathogenic role for C5a in ALS (Woodruff et al., 2008a). Chronic administration of a 
specific C5a receptor antagonist, developed in our laboratories (Wong et al., 1998) in hSOD1
G93A
 
transgenic rats, markedly delayed the onset of motor symptoms and increased survival, compared to 
untreated animals (Woodruff et al., 2008a). We also showed up-regulation of CD88 in the lumbar 
spinal cord of hSOD1
G93A
 transgenic rats, which increased as disease progressed (Woodruff et al., 
2008a). 
 
These findings of up-regulated complement components in different animal models of ALS suggest 
that the activation of complement system is critically linked with disease progression in ALS. 
Whilst inhibition of classical, lectin and alternative complement pathways (C1q, C3 and C4) failed 
to ameliorate disease in hSOD1 transgenic mice, inhibition of the classical receptor for C5a, CD88, 
reduced disease pathology and extended survival in hSOD1
G93A
 transgenic rats. It should be noted 
that C5a is expressed following activation of all complement pathways (Figure 1.1), and can also 
be generated in the absence of C3 and other upstream complement factors (Huber-Lang et al., 
2006). Hence inhibiting central components of the complement system, at the C5 level, may have 
benefits in slowing disease progression in ALS, as opposed to inhibiting an individual activation 
pathway. Specifically, our studies suggest that inhibiting the pro-inflammatory C5 activation 
fragment, C5a, which is central to, and generated by, all complement pathways, may be a novel 
therapeutic strategy to treat ALS. 
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Table 1.2 Experimental evidence of complement activation in animal models of ALS 
 
Complement 
factors 
mRNA/Protein Transgenic model Reference 
C1q mRNA Mouse SOD1 
G93A
 (Perrin et al., 2005) 
C1q, DAF mRNA 
Mouse SOD1 
G37R
 and 
SOD1 
G85R
 
(Lobsiger et al., 2007) 
C1q, C4 mRNA/Protein Mouse SOD1 
G93A
 (Ferraiuolo et al., 2007) 
C1q mRNA Mouse SOD1 
L126delTT
 (Fukada et al., 2007) 
CD88 mRNA/Protein Rat SOD1 
G93A
 (Woodruff et al., 2008a) 
CD88 mRNA/Protein Mouse NFL -/- (Humayun et al., 2009) 
C1q, C3 mRNA/Protein Mouse SOD1 
G93A
 (Heurich et al., 2011) 
 
1.10 Rationale, Hypothesis and Aims 
There is increasing evidence that implicates the involvement of the innate immune system in the 
progression of ALS. In particular, the inappropriate activation or dysregulation of the complement 
system may play a role in ALS pathology. Evidence for this includes elevated levels of complement 
activation fragments in the serum, CSF, spinal cord and motor cortex of ALS patients. This has also 
been supported with elevated levels of complement activation fragments in various animal models 
of ALS. Moreover, inhibition of the C5a receptor using a specific C5a receptor antagonist 
ameliorated disease symptoms in a rat model of ALS. Collectively, these studies suggest that 
complement activation at the level of C5, may play a crucial role in the progression of ALS. Hence 
reducing complement-induced inflammation using inhibitors to target the C5-C5a receptor axis, 
could be an important therapeutic strategy to treat ALS. 
 
Based on the current knowledge of complement activation in ALS, I hypothesised that downstream 
complement components including CD88 and C3aR may be the key point at which complement 
mediated neurotoxicity occurs in the hSOD1
G93A
 ALS mouse model. More specifically I propose 
that inhibition of CD88 will have improved disease symptoms and extended survival whereas 
inhibition of C3aR will have worsened disease symptoms with reduced survival. In order to 
investigate these hypotheses I aimed to: 
 
1) Examine the expression and cellular localisation of C3, C5 and their receptors C3aR and CD88 
in hSOD1
G93A
 mice during disease progression,  
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2) Elucidate the function and mechanism of CD88 using the CD88 selective antagonist PMX205 in 
hSOD1
G93A
 mice and follow these pharmacological studies by utilising hSOD1
G93A
 mice lacking 
CD88. 
 
3) Understand the role of C3aR in the disease progression of ALS using hSOD1
G93A
 mice lacking 
C3aR. 
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CHAPTER 2 
“Methods” 
 
2.1 Ethical Statement 
All experimental procedures were approved by the University of Queensland Animal Ethics 
Committee (Permit Number: 227-09, 433-12, 047-11, 033-12), and complied with the policies and 
regulations regarding animal experimentation and other ethical matters (Drummond and Sorenson, 
2009). They were conducted in accordance with the Queensland Government Animal Research Act 
2001, associated Animal Care and Protection Regulations (2002 and 2008), the Australian Code of 
Practice for the Care and Use of Animals for Scientific Purposes, 7th Edition (National Health and 
Medical Research Council, 2004). ARRIVE guidelines have been followed in the preparation of 
this thesis. 
 
2.2 Animals  
Transgenic hSOD1
G93A
 mice (B6-Cg-Tg (SOD1-G93A) 1Gur/J) were obtained from Jackson 
laboratory (Bar Harbor, ME, USA). Homozygous C5aR deficient (C5aR
-/-
) and C3aR deficient 
(C3aR
-/-
) mice were kindly provided by Dr. Wetsel and described previously (Hollmann et al., 
2008, Kildsgaard et al., 2000). These animals were maintained at the University of Queensland 
Biological Resources Animal Facilities under specific pathogen free conditions. All animals were 
housed in a 12h light/dark cycle with free access to food and water. 
 
hSOD1
G93A
 transgenic mice express high levels of the human SOD1 mutant protein (~25 
copies)(Alexander et al., 2004), in which glycine residue is replaced with an alanine residue at 
position 93 (Gurney, 1994). The SOD1 mutation causes a toxic gain-of-function rather than 
diminished SOD1 activity (Wong et al., 1995). It is considered to be a reliable model for human 
ALS as transgenic mice carrying mutant forms of SOD1 develop progressive muscle deficits very 
similar in phenotype (tremor and eventual paralysis) and histopathological hallmarks (selective grey 
matter degeneration) to human ALS (Gurney, 1997). hSOD1
G93A
 mice at four predefined stages of 
ALS were used throughout the thesis (Table 2.1). By the end stage of ALS, hSOD1
G93A
 mice 
display significant signs of hind-limb weakness, paralysis and loss of the righting reflex. 
 
To generate hSOD1
G93A
 mice lacking C5aR (hSOD1
G93A
 x C5aR
-/-
) and C3aR (hSOD1
G93A
 x C3aR
-
/-
), transgenic heterozygous hSOD1
G93A
 male were first cross-bred with C5aR
-/-
 and C3aR
-/-
 females 
to generate F1 progeny (hSOD1
G93A
 x C5aR
+/-
 and hSOD1
G93A
 x C3aR
+/-
). hSOD1
G93A
 x C5aR
+/-
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and hSOD1
G93A
 x C3aR
+/-
 males were cross bred with C5aR
-/-
 and C3aR
-/-
 females to obtain F2 
progeny (hSOD1
G93A
 x C5aR
-/-
 and hSOD1
G93A
 x C3aR
-/-
) (Figure 2.1).  
 
All mice were anaesthetized with intraperitoneal injection of zolazapam (50mg/kg; Zoletil, 
Lyppard, Australia) and xylazine (10mg/kg; Xylazil, Lyppard, Australia) prior to the collection of 
tissue samples. 
 
Table 2.1: Different stages defined in ALS 
Stage Age Phenotype 
Pre-symptomatic  30 days postnatal No signs of motor deficit 
Onset  70 days postnatal Initial signs of motor deficit (grip strength) 
Mid-symptomatic 130 days postnatal Weakness in hind-limb and tremor when 
suspended by the tail 
End 150 to 175days postnatal Full paralysis of lower limbs and loss of righting 
reflex 
18 
 
 
Figure 2.1: The breeding scheme to obtain hSOD1
G93A
 mice lacking C5aR and C3aR. To 
generate hSOD1
G93A
 mice lacking C5aR (hSOD1
G93A
 x C5aR
-/-
) and C3aR (hSOD1
G93A
 x C3aR
-/-
), 
transgenic heterozygous hSOD1
G93A
 male were first cross-bred with C5aR
-/-
 and C3aR
-/-
 females to 
generate F1 progeny (hSOD1
G93A
 x C5aR
+/-
 and hSOD1
G93A
 x C3aR
+/-
). hSOD1
G93A
 x C5aR
+/-
 and 
hSOD1
G93A
 x C3aR
+/-
 males were cross bred with C5aR
-/-
 and C3aR
-/-
 females to obtain F2 progeny 
(hSOD1
G93A
 x C5aR
-/-
 and hSOD1
G93A
 x   C3aR
-/-
). 
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2.3 Drug Treatment and experimental design 
2.3.1 PMX205  
PMX205 (hydrocinnamate-[OP (D-Cha) WR]) is an orally active cyclic hexapeptide developed in 
our laboratory at the University of Queensland (March et al., 2004). This compound is based on the 
linear C5aR antagonist, Me-FKPdChaWR and the eventual cyclisation to induce structural and 
metabolic stability (March et al., 2004). This drug has been shown to reduce pathology in numerous 
rodent models of inflammatory disease including rheumatoid arthritis (Woodruff et al., 2002), 
ischemic reperfusion injuries (Arumugam et al., 2004) and inflammatory bowel disease (Woodruff 
et al., 2003), as well as acute neurotrauma (Beck et al., 2010). PMX205 is more lipophilic than the 
previous C5aR antagonist PMX53, which results in increased CNS penetrance across the blood 
brain barrier (Woodruff et al., 2006). Hence, it has been shown to be more efficacious to reduce 
disease severity and prolong survival in animal models of neural degeneration (Woodruff et al., 
2008a, Fonseca et al., 2009, Ager et al., 2010, Woodruff et al., 2006). 
 
2.3.2 Drug Regime 
PMX205 was administered orally in drinking water at a dose of 3mg/kg/day and 9mg/kg/day. 
Litter-matched female hSOD1
G93A
 transgenic mice were administered PMX205 from 35 days 
postnatal, which is approximately 35 days before initial motor deficit symptoms hence termed “Pre-
Onset”. PMX205 was also administered from 91 days postnatal at 9mg/kg/day which is 
approximately 21 days after initial motor deficit symptoms hence termed “Post-Onset”. These drug 
treatments were continued till end-stage of disease progression in these mice. These treatments were 
performed blinded to the researcher.  
 
2.4 Disease progression and survival analysis 
The rate of disease progression in all these mice was determined by age at which maximal grip 
strength decline at 25, 50, 75 and 100% throughout disease progression. Survival (or rather “death”) 
was determined by the inability of the animal to right itself within 30 seconds if laid on either side. 
This is a widely accepted and published endpoint for life span studies in ALS mice and guarantees 
that euthanasia occurs prior to the mice being unable to reach food or water (Ludolph et al., 2007, 
Scott et al., 2008).  
 
2.5 Weight Measurements and Behavioural Tests 
All mice (including hSOD1
G93A
, wild-type (WT), hSOD1
G93A
 x C3aR
-/-
 and C3aR
-/-
) were weighed 
weekly at the same time of day (4 p.m.), from 42 days of age until end-stage when they lose their 
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righting reflex. Two neuromotor tests the rota-rod and hind-limb grip strength test, were conducted 
on these mice (detailed below).  These tests were performed blinded to the genotype.  
 
2.5.1 Rota-rod Test 
Mice were tested for their motor coordination from 42 days of age using a Rota-rod apparatus (Ugo 
Basile Rota-rod, Italy) at a constant speed of 20 rpm. Each mouse was given three attempts and the 
longest latency to fall was recorded; 180s was chosen as the arbitrary cut off time. One week prior 
to the test, mice were trained twice to remain on the Rota-rod apparatus to exclude differences in 
motivation and motor learning. In the training phase, mice were placed on the Rota-rod at a constant 
speed of 20 rpm for a maximum duration of 240s (Zhou et al., 2007). 
 
2.5.2 Hind-limb grip strength Test 
A digital force gauge (Ugo Basile) was used to measure maximal muscle grip strength. The mice 
were held by their tail and lowered until the mice grasped the T-bar connected to the digital force 
gauge with their hind limbs. The tail is lowered until the body is horizontal and the mice are pulled 
away from the T-bar with a smooth steady pull until both of their hind limbs released the bar. The 
digital force gauge will remain fixed at its maximum deflection and the strength of the grip was 
measured in gram force. Each mouse was given ten attempts and the maximum grip strength was 
recorded. 
 
2.6 Immunohistochemistry 
hSOD1
G93A
 and WT mice were fixed by transcardiac perfusion with 2% sodium nitrite buffer (Ajax 
Finechem Pty Ltd, Australia) followed by 4% paraformaldehyde (PFA; Sigma, MO, USA) in 0.1M 
Phosphate buffer pH7.4 (PB). The lumbar spinal cords were collected and then placed in 4% PFA 
for another 2 hours at 4°C. The lumbar spinal cords were embedded in OCT (Sakura, CA, USA) 
and snap frozen in liquid nitrogen. Serial transverse cryosections (16µm) were collected on 
Superfrostplus slides (Menzel-Glaser, Braunschweig, DEU) for estimation of motor neuron 
numbers and fluorescence immunohistochemistry. 
 
For the motor neuron numbers in the spinal cord, the sections are stained using 0.1% thionin (v/v) 
in acetic acid buffer solution (Sigma) for 3 minutes. The sections were rinsed in distilled water 
before being mounted with xylene-soluble mounting medium (ProSciTech, Australia). The lumbar 
lateral motor column (LMC) extending from the 2
nd
 lumbar dorsal root ganglia (DRG) to the 6
th
 
lumbar DRG was selected from our serial spinal sections, with the aid of mouse brain atlases 
(Watson, 2009). α - motor neurons within the lumbar LMC were identified as a large motor neurons 
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that showed a dark stained cytoplasm, a distinct pale nucleus and dark stained nucleoli (Banks et al., 
2001, Banks et al., 2005, Clarke and Oppenheim, 1995). They were counted on both sides of the 
spinal cord in every tenth sections. The total number of motor neurons counted was divided by the 
number of sections counted and multiplied by the total number of sections containing the lumber 
LMC. The mouse genotypes were not made available to the researcher conducting the counts until it 
was completed. 
 
Fluorescence double labelling was performed to localise the expression of C1q, C3b, C3, C5 and its 
receptors C3aR and CD88 with specific cell-type markers for motor neurons (choline 
acetyltransferase (ChAT)), astrocytes (glial fibrillary acidic protein (GFAP)) and microglia 
(ionised calcium binding adaptor molecule 1 (Iba-1) and cluster of differentiation molecule 11b 
(CD11b)). All sections were rehydrated in phosphate buffered saline pH 7.4 (PBS) and blocked in 
PBS containing 3% bovine serum albumin (BSA) or 3% donkey serum and 1% BSA for 1 hour at 
room temperature. Next, sections were incubated overnight at 4°C with a combination of antibodies 
outlined in table 2.2. All primary antibodies were diluted in PBS containing 1% BSA or 1% donkey 
serum. These sections were then washed 3 x 10 mins with PBS prior to incubation with an 
appropriate Alexa conjugated secondary cocktail: Alexa 555 goat anti-rat, Alexa 555 goat anti-
mouse, Alexa 555 goat anti-chicken, Alexa 594 donkey anti-rat, Alexa 555 donkey anti-mouse, 
Alexa 555 donkey anti-chicken, Alexa 488 goat anti-mouse, Alexa 488 goat anti-rabbit, Alexa 488 
goat anti-rat and Alexa 488 donkey anti goat. All secondary antibodies were diluted in PBS 
containing 1% BSA or 1% donkey serum (1:1000 for Alexa 555/594 and 1:600 for Alexa 488). 
Following 3 x 5min washes in PBS, the sections were incubated for 5min in 4, 6-diamidino-2-
phenylindole (Life Technologies, USA). All sections were mounted with Prolong Gold Anti-Fade 
medium (Invitrogen). IgG negative controls (mouse IgG2a, Serotec; rat IgG2a, Serotec; chicken 
IgY, Promega) were used in place of primary antibodies to give a measure of non-specific 
background staining. These IgG and IgY control antibodies were used at the same concentrations 
and were of the same species to the primary antibodies listed above. Images were taken with a Zeiss 
LSM Meta 510 upright confocal microscope using a Plan-Apochromat 63x oil objective (Carl Zeiss 
Inc; Oberkochen, Germany).   
 
Quantification of immunofluorescence for C1q and C3b was performed on ~ 25 to 35 lumbar spinal 
cord sections (per animal; n=3) spaced 160µm apart and expressed as percentage immuno-reactive 
area per section. Staining procedures and image exposures were all standardized between genotype 
and between sections.  
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Table 2.2 Summary of antibodies used for immunohistochemistry 
Antibody Manufacturer Dilution In combination with 
Rat anti-mouse C1q Hycult Biotechnology 1:1,000 GFAP, Iba-1, ChAT 
Rat anti-mouse C3b Hycult Biotechnology 1:50 GFAP, Iba-1, ChAT 
Mouse anti-mouse C5 Hycult Biotechnology 1:1,000 GFAP, CD11b, ChAT 
Rat anti-mouse CD88 AbD Serotec 1:250 GFAP, Iba-1, ChAT 
Rat anti-mouse C3 Hycult Biotechnology 1:50 GFAP, Iba-1, ChAT 
Chicken anti-mouse C3aR BMA Biomedicals 1:1,000 GFAP, Iba-1, ChAT 
Mouse anti-mouse GFAP BD Biosciences 1:1,000 C1q, C3b, C5, CD88, C3, C3aR 
Rabbit anti-mouse Iba-1 Wako 1:400 C1q, C3b, CD88, C3, C3aR 
Rat anti-mouse CD11b Abcam 1:300 C5 
Goat anti-mouse ChAT Chemicon 1:100 C1q, C3b, C5, CD88, C3, C3aR 
 
2.7 Real time quantitative PCR 
Lumbar spinal cords from all the mice (including hSOD1
G93A
, WT, hSOD1
G93A
 x C5aR
-/-
, C5aR
-/-
, 
hSOD1
G93A
 x C3aR
-/-
 and C3aR
-/-
) were collected into RNAlater (Ambion, NY, USA) and stored at 
-20°C for subsequent quantitative PCR analysis. Total RNA was isolated using RNeasy Lipid 
Tissue extraction kit according to manufacturer’s instructions (QIAGEN, CA, USA). After the total 
RNA was purified using Turbo DNAse treatment (Ambion), cDNA was synthesized using 
Stratagene RT kit (Agilent Technologies, CA, USA). Commercially available gene specific 
TaqMan probes and SYBR green (Applied Biosystems, USA) were used to amplify target gene of 
interest. All probes and primers used are listed in table 2.3 and 2.4 respectively. Relative target 
gene expression to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was determined using 
this formula: 2
-∆CT where ∆Ct = (Ct target gene – Ct GAPDH) (Livak and Schmittgen, 2001). Final 
measures are presented as relative levels of gene expression in hSOD1
G93A
, hSOD1
G93A
 x C5aR
-/-
, 
C5aR
-/-
, hSOD1
G93A
 x C3aR
-/-
 and C3aR
-/-
 mice compared with expression in WT controls. 
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Table 2.3: Taqman probes used for quantitative PCR 
Gene of interest Catalogue number 
C1qB Mm01179619_m1 
C4 Mm00437896_g1 
Factor B Mm00433909_m1 
C3 Mm01232779_m1 
CD55 Mm00438377_m1 
CD59a Mm00483149_m1 
C5 Mm00439275_m1 
CD88 Mm00500292_s1 
C3aR Mm01184110_m1 
Glyceraldehyde-3-phosphate dehydrogenase Mm99999915_g1 
Mannose binding lectin 1 Mm00495413_m1 
Mannose binding lectin 2 Mm00487623_m1 
Tumour Necrosis Factor Mm00443258_m1 
Interleukin-1β Mm00434228_m1 
Entpd1 Mm00515447_m1 
Ly6C 1/2 Mm03009946_m1  
 
 
Table 2.4: List of primers used for SYBR Green quantitative PCR 
Gene of interest Primer Sequence Product Length 
Iba-1 Forward: 5` - ACAGCAATGATGAGGATCTGC - 3` 
Reverse: 5` - CTCTAGGTGGGTCTTGGGAAC - 3` 
146 
GFAP Forward: 5` - TCCTGGAACAGCAAAACAAG - 3` 
Reverse: 5` - CAGCCTCAGGTTGGTTTCAT - 3` 
224 
GAPDH Forward: 5` - CCAGGAGCGAGACCCCACTAACA - 3` 
Reverse: 5` - TCGGCAGAAGGGGCGGAG - 3` 
150 
 
 
 
 
 
24 
 
2.8 Western blot Analysis 
Lumbar spinal homogenates from hSOD1
G93A
 and WT mice were resolved on a 10% sodium 
dodecyl sulphate polyacrylamide gel and electro transferred onto nitrocellulose membranes. 
Membranes were blocked in 2.5% skim-milk-Tris buffered solution- 0.1% Tween 20 (TBS-T) for 
CD88 and 5% BSA-TBS-T for CD55 and incubated overnight with one of the following antibodies; 
anti-CD88 (1:1000; BMA Biomedical, Switzerland), or anti-CD55 (1:1000; Hycult Biotechnology, 
Netherlands). All primary antibodies were diluted in 5% BSA-TBS-T. Anti-CD88 was detected 
with goat anti-chicken horseradish peroxidase (HRP; 1:15,000; GE Healthcare, PA, USA) and anti-
CD55 was detected with goat anti-rat HRP (1:10,000; GE Healthcare). These secondary antibodies 
were detected by enhanced chemiluminescence (Amersham, PA, USA). Blots were stripped and re-
probed with anti-GAPDH, (1:15,000; Millipore, MA, USA) and detected with sheep anti-mouse 
HRP (1:4,000; GE Healthcare) to ensure equal protein loading. Densitometric analyses of immuno-
reactive bands were performed by deducting background pixels from grayscale pixel density of 
bands multiplied by its area value using Image J software (Abramoff, 2004). The integrated pixel 
value for each band was normalized to its corresponding anti-GAPDH band. The normalized 
integrated pixel values of hSOD1
G93A
 bands were compared to WT bands.  
 
2.9 In situ hybridisation 
hSOD1
G93A
 transgenic mice and WT mice were euthanized by cervical dislocation. The lumbar 
spinal cord were collected and then fixed overnight in 4% PFA in 1 x PBS at 4°C. Following this 
incubation, lumbar spinal cord was washed 3 x 5min in 1 x PBS , followed by submersion overnight 
in sucrose solution at 10% and 25% in 1 x PBS . The lumbar spinal cords was embedded in a 
cryoprotectant mounting medium (optimal cutting temperature; OCT, Sakura Fineteck, USA) and 
snap frozen in liquid nitrogen. Lumbar spinal cords were sectioned using a cryostat (Leica 3050n) 
into 16μm thick transverse sections and dry mounted onto a Superfrost (+) slides for in situ 
hybridization detailed below. 
 
Digoxygenin (DIG)-labelled RNA probes will be generated from PCR derived templates using T3 
and T7 RNA polymerases by adding T3 (5’ – AATTAACCCTCACTAAAGGG – 3’) and T7 (5’ – 
TAATACGACTCACTATAGGG – 3’) RNA polymerase promoter sequences to the primers 
specific for CD88;Forward –TAATACGACTCACTATAGGGATCATCTACTCGGTGGTGTTCC 
and Reverse - AATTAACCCTCACTAAAGGGGAGAGACCTTAGGAGTCGTCCA. A standard 
PCR is performed and the PCR product is run on a 1% agarose gel. The band corresponding to my 
gene of interest will be excised and purified using Min-elute gel extraction kit (Qiagen) according 
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to manufacturer’s instructions. DIG – labelled RNA probes will be synthesized using DIG RNA 
labelling mix (Roche) according to manufacturer’s instructions.  
 
Sections will be re-hydrated in 1 x PBS for 5 minutes and post fixed in 4% PFA in 1 x PBS for 15 
minutes and treated with Proteinase K (30µg/ml) for 10 minutes at room temperature. Sections will 
be acetylated for 10 minutes (acetic anhydride, 0.25%; Sigma) and hybridized with DIG-labelled 
probes overnight at 65°C. Hybridisation buffer contains 1 x salts (200mM sodium chloride, 13mM 
tris, 5mM sodium phosphate monobasic, 5mM sodium phosphate dibasic, 5mM EDTA), 50% 
formamide, 10% dextran sulfate, 1mg/ml yeast tRNA (Roche), 1 x Denhardt’s (1% w/v bovine 
serum albumin, 1% w/v Ficoll, 1% w/v polyvinylpyrrolidone) and DIG-labelled probe (1:2000). 
Sections will be washed in post-hybridisation buffer (1 x SSC, 50% formamide, 0.1% Tween-20) 
for 2 x 10 minutes at 65°C followed by 2 x 15 minutes washes in 1 x MABT (150mM sodium 
chloride, 100mM maleic acid, 0.1% Tween-20, pH 7.5) at room temperature, then will be followed 
by RNAse treatment (400mM sodium chloride, 10mM tris pH 7.5, 5mM EDTA, 20ug/ml RNAse 
A) for 30 minutes at 37°C. Sections will be blocked in blocking solution (1 x MABT, 2% blocking 
reagent (Roche), 20% hear inactivated goat serum) for 1 hour at room temperature and incubated 
overnight at 4°C with anti-DIG antibody (1:2500 in blocking solution). Sections will be then 
washed in 1 x NTMT (100mM sodium chloride, 50mM magnesium chloride, 100mM tris pH 9.5, 
0.1% Tween-20), followed by incubation in NBT/BCIP in 1 x NTMT according to manufacturer’s 
instructions (Promega). Slides will be counterstained with nuclear fast, dehydrated and cleared in 
xylene and mounted in cytoseal mounting medium (VWR). 
 
2.10 ELISA 
96-well plates (Greiner Bio-One, Frickenhausen, Germany) were pre-coated with monoclonal rat 
anti-mouse C5a capture antibody (Clone I52 – 1486; BD Pharmingen, San Diego, CA, USA) 
diluted in coating buffer (100μM, NaHCO3, 34μM Na2CO3, pH 9.5) overnight at 4°C in a sealed 
humidified container. This capture antibody is specific for a neo-epitope exposed only in mouse 
C5a/C5a desArg and does not cross-react with C5 (Pavlovski et al., 2012, Wu et al., 2013). 
Following the plate being blocked for 1 hour at room temperature with assay diluent (10% 
FCS/PBS), C5a standard and lumbar spinal cord homogenates was incubated for 2 hours at room 
temperature. The plates were subsequently incubated with biotinylated rat anti-mouse C5a detection 
antibody (clone I52-278; BD Pharmingen) for 1 hour at room temperature, and then incubated with 
Streptavidin-HRP conjugate for 30 minutes at room temperature. Tetramethylbenzidine (Sigma) 
substrate was used as the chromogen and the plate was read at 450nm. Levels of C5a in lumbar 
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spinal cord samples were adjusted to micrograms per protein and expressed as nanograms of C5a 
per microgram of protein. 
 
 
2.11 Statistical Analysis 
All measures were performed using GraphPad Prism 5.0 (San Diego, CA, USA). The statistical 
differences between different cohort of animals for body weight, rota-rod test and hind-limb grip 
strength test, were analysed using two-tailed Student’s t-test at each time point. For the results from 
motor neuron counts, quantitative real time PCR, western blotting, ELISA, statistical differences 
between different cohorts of animals was analysed using two-tailed t-test at each stage of disease 
progression. All data are presented as mean ± SEM and differences were considered significant 
when P ≤ 0.05.   
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CHAPTER 3 
“Dysregulation of the complement cascade in the hSOD1G93A transgenic mouse model of 
amyotrophic lateral sclerosis” 
* This chapter was published in Journal of Neuroinflammation - John D Lee, Nur A 
Kamaruzaman, Jenny NT Fung, Stephen M Taylor, Bradley J Turner, Julie D Atkin, Trent M 
Woodruff and Peter G Noakes (2013) Dysregulation of complement cascade in the hSOD1
G93A 
transgenic mouse model of amytrophic lateral sclerosis. Journal of Neuroinflammation. 10:119 
 
3.1 INTRODUCTION 
Amyotrophic lateral sclerosis (ALS) is a late onset neurodegenerative disorder that is characterized 
by selective loss of upper motor neurons within the motor cortex, and α-motor neurons of the spinal 
cord and brainstem (Bruijn et al., 2004). This results in symptoms of muscle weakness and atrophy 
of skeletal muscles, leading to paralysis and eventual death due to failure of respiratory muscles 
(Cozzolino et al., 2008). The mechanisms leading to ALS are still unclear but there are compelling 
data that suggest neuro-inflammation may contribute to the disease progression of ALS (Bruijn et 
al., 2004, Woodruff et al., 2008b, Lee et al., 2012). These include the presence of reactive microglia 
and astrocytes, infiltration of T lymphocytes and up-regulation of cyclooxygenase 2 and 
prostaglandin E2 in the spinal cord of ALS patients and animal models (Almer et al., 2001, Almer et 
al., 2002, McGeer and McGeer, 2002, Henkel et al., 2013, Zhao et al., 2012). The classical 
complement system is also implicated in ALS pathology, as studies have shown activation 
fragments of complement components C1q, C3 and C4 are increased in the serum, cerebrospinal 
fluid and neurological tissue (including spinal cord and motor cortex) of ALS patients (Lee et al., 
2012). 
 
In addition to evidence suggesting complement involvement in human ALS pathology, several 
studies have demonstrated the involvement of complement factors in animal models of ALS. The 
up-regulation of the classical pathway complement components C1q and C4, as well as of the 
central factor C3, has been shown in human SOD1 transgenic rodent models of ALS (Lee et al., 
2012). Other studies have also shown the up-regulation of the major pro-inflammatory C5a 
receptor, CD88, during disease progression (Humayun et al., 2009, Woodruff et al., 2008a). In 
addition, our group has shown that chronic administration of a specific CD88 antagonist in 
hSOD1
G93A
 transgenic rats delayed the onset of motor symptoms and increased survival compared 
to untreated animals (Woodruff et al., 2008a). Overall, these studies indicate that over-activation of 
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complement system, and increased C5a-CD88 signalling contributes to the progression of disease in 
these animal models of ALS. 
 
In the present study, we examined the expression and cellular location of major complement factors 
and regulators during defined disease stages in hSOD1
G93A
 mice in order to provide a 
comprehensive overview of complement’s involvement in ALS. Additionally, given the importance 
of C5a in disease pathology in ALS models (Humayun et al., 2009, Woodruff et al., 2008a) we also 
examined mRNA, protein levels, and the cellular localisation of C5, C5a and its cognate receptor, 
CD88 during disease progression. Our findings demonstrate a global dysregulation of complement, 
as disease progressed in these murine models of human ALS.  
 
3.2 RESULTS 
3.2.1 Motor deficits in hSOD1
G93A
 mice correlate with lumbar motor neuron loss during 
disease progression. 
To monitor the decline in neuromotor performance and loss of motor neurons during ALS 
progression in hSOD1
G93A
 mice, body weights, motor behavioural tests and motor neuron counts 
were performed. The onset of disease was defined as a stage in which a neuromotor deficit was 
measurable. In this study, hSOD1
G93A
 mice showed a decrease in their body weight, hind-limb grip 
strength and rota-rod performance when compared to wild-type (WT) mice. The weight of the 
hSOD1
G93A
 mice reached the maximum at 133 days of age and was significantly decreased when 
compared to WT mice at 140 days (mean body weight, hSOD1
G93A
 = 20.4 ± 0.23g and WT = 22.3 ± 
0.25g, n = 9, * P < 0.05, # P < 0.001; arrow in Figure 3.1A).  
 
Rota-rod is a widely used measure of neuromotor performance in hSOD1
G93A
 mice (Mead et al., 
2011). In our study, both hSOD1
G93A
 and WT mice remained on the Rota-rod for the full duration 
of the test until 119 days when hSOD1
G93A
 mice showed ~30% reduction in the time remained on 
the rota-rod (n = 12, * P < 0.05, # P < 0.001; arrow in Figure 3.1B). Next, we measured maximal 
hind-limb grip strength as an alternate measure of neuromotor function (Lepore et al., 2007, Schafer 
and Hermans, 2011). At 70 days, hSOD1
G93A
 mice showed a significant reduction in grip strength 
(~35% reduction; n = 12, * P < 0.05, + P < 0.01, # P < 0.001) when compared to WT mice (arrow 
in Figure 3.1C). Our results suggest that the hind-limb grip strength test is a more sensitive 
measure of detecting motor deficit symptoms in hSOD1
G93A
 mice compared to weight loss and rota-
rod performance (Schafer and Hermans, 2011). The Rota-rod test mainly evaluates balance and co-
ordination, and does not necessarily reflect muscle denervation (i.e. loss of muscle function; (Weydt 
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et al., 2003)). By contrast, the decline in grip strength in the hSOD1
G93A
 mice closely correlated 
with the onset of lumbar motor neuron loss at 70 days (n = 6, *** P < 0.001; Figure 3.1D).  Post 70 
days, we observed further declines in hind-limb grip strength presumably resulting from a 
progressive drop in lumbar motor neuron numbers up to end-stage (Figure 3.1C and D).   
 
 
 
 
Figure 3.1: Decline in motor performance during ALS progression correlates with lumbar motor 
neuron loss in the lumbar spinal cord of hSOD1
G93A
 mice. A shows significant weight loss of 
hSOD1
G93A
 mice when compared to wild type (WT) control mice at 140 days of age (arrow, n = 12, 
* P < 0.05, # P < 0.001, student t-test). B and C show significant reduction in time spent on rota-
rod and hind-limb grip strength for hSOD1
G93A
 versus WT mice, at 119 days and 70 days 
respectively (arrows, n = 12, * P<0.05, + P<0.01, # P<0.001, student t-test). D shows lumbar 
motor neuron loss in hSOD1
G93A
 mice when compared to WT control mice at 70 days of age 
onwards (n = 6, *** P<0.001, student t-test). The decline in motor neuron number at 70 days 
correlates with the onset of loss of hind limb muscle strength at this same age (C). Data expressed 
as mean ± SEM. PS = pre-symptomatic (30 days postnatal [P30]); OS = onset (70 days postnatal 
[P70]); MS = mid-symptomatic (130 days postnatal [P130]) and ES = end-stage (175 days 
postnatal [P175]). 
 
 
30 
 
3.2.2 Components of the classical and alternate pathways of complement are up regulated 
along with decreased expression levels of complement regulators in hSOD1
G93A
 mice. 
Previous studies have identified various members of the complement system are up regulated in 
ALS and in ALS animal models, however it is unclear which of the major complement pathways 
are being activated. To investigate this further, we examined the mRNA and protein levels for some 
of the key initiators of the complement pathways, the classical, alternate and lectin pathway, as well 
as the major complement regulators CD55 and CD59a (Woodruff et al., 2010).  
 
The expression levels of initiating components of the classical pathway (C1qB and C4), the 
alternative pathway (factor B), the lectin pathway (mannose binding lectin 1 and 2 (MBL1 and 
MBL2)), the central component common to all pathways - C3, and the complement regulators 
CD55 and CD59a were measured in the lumbar spinal cord of hSOD1
G93A
 mice during disease 
progression of ALS (30 days to 175 days). This was achieved using one or combination of the 
following: quantitative real time PCR, immunofluorescence and/or western blotting. C1qB and C4 
transcripts were significantly increased by 1.2 fold and 1.3 fold at onset, 1.7 fold and 2.9 fold at 
mid-symptomatic, and 13.1 fold and 10.7 fold by end stage of disease in hSOD1
G93A
 mice when 
compared to WT mice respectively (n = 6, * P < 0.05, ** P < 0.01 and *** P < 0.001; Figure 3.2A 
and Figure 3.4D). Up-regulation of C1q at end-stage was confirmed using immunofluorescence 
where there was marked increase in hSOD1
G93A
 mice compared to WT mice (Figure 3.2B). We 
also examined that marked increase of C1q in hSOD1
G93A
 mice was localised to motor neurons and 
activated microglia (white arrows in Figure 3.2L-N [detailed in 3.2U], and white arrows in Figure 
3.2R-T [detailed in 3.2W]), compared to WT, where little to no C1q was observed (Figure 3.2C-E 
and Figure 3.2I-K). We did not observe C1q on GFAP expressing astrocytes in either hSOD1
G93A
 
or WT mice (Figure 3.2O-Q [detailed in 3.2V] for hSOD1
G93A
 mice; Figure 3.2F-H for WT mice). 
Factor B  showed a similar activation profile to that of C1qB and C4, namely there was a 2.2 fold 
increase in mRNA at mid-symptomatic and by end-stage of disease, there was a 6.0 fold increase in 
hSOD1
G93A
 mice respectively compared with WT mice (n=6, * P < 0.05, *** P < 0.001; Figure 
3.4E).  
 
The central component of complement system C3 was also increased in hSOD1
G93A
 mice, however 
its expression profile only dramatically increased by end stage in hSOD1
G93A
 mice when compared 
to WT.  Specifically, we observed 1.8 and 1.6 fold increases at onset and mid-symptomatic with a 
dramatic 10.2 fold increase in C3 mRNA by end-stage of disease when compared to WT mice (n=6, 
* P < 0.05 and *** P < 0.001; Figure 3.3A). We then examined the expression and localisation of 
its activation fragment C3b in hSOD1
G93A
 and WT mice at end stage. Increased immunolabeling for 
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C3b was observed in the lumbar spinal cords of hSOD1
G93A
 mice compared to WT mice, at end-
stage (Figure 3.3B). In hSOD1
G93A
 mice, C3b deposition appeared primarily on motor neurons and 
microglia (white arrows in Figure 3.3L-N [detailed in 3.3U], and white arrows in Figure 3.3R-T 
[detailed in 3.3W]), compared to WT, where there was little to no C3b staining (Figure 3.3C-E, 
and white arrows in Figure 3.3I -K). We did not observe C3b staining on GFAP expressing 
astrocytes in either hSOD
G39A
 or WT mice (Figure 3.3O-Q [detailed in 3.3V] for hSOD1
G93A
 mice, 
and Figure 3.3F-G for WT mice). Changes in mRNA expression level of MBL1 and MBL2, which 
are the initiating components of the lectin pathway, were not detectable in either hSOD1
G93A
 or WT 
mice (data not shown), suggesting this pathway plays a minor role in this model.   
 
The regulators of complement system CD55 and CD59a were also investigated, as they are 
important in maintaining homeostasis and keeping the complement system in its proper 
physiological state. Specifically, CD55 and CD59a negatively regulate complement activation by 
accelerating C3 convertase decay and inhibiting the assembly of membrane attack complex 
respectively (Spendlove et al., 2006, Kimberley et al., 2007). CD55 mRNA expression was initially 
increased by 1.4 fold at pre-symptomatic, and decreased at mid-symptomatic and end stage of 
disease by 0.4 fold and 0.5 fold respectively when compared to WT (n=6, * P < 0.05 and *** P < 
0.001; Figure 3.4A). This was confirmed at protein level using western blotting, where a 41kDa 
CD55 immuno-reactive band was observed in all stages of hSOD1
G93A
 mice and their respective 
WT mice (Figure 3.4B, upper panel). Semi-quantitative densitometry analyses of these bands with 
respect to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) loading controls (Figure 3.4B, 
lower panel), revealed increased CD55 protein in the lumbar spinal cord of hSOD1
G93A
 mice by 3.2 
fold at pre-symptomatic and decreased by 0.7 fold at mid-symptomatic and 0.6 fold at end stage 
respectively, when compared to WT mice (n=4, * P < 0.05 and ** P < 0.01; Figure 3.4C). CD59a 
mRNA was also increased initially at onset by 1.3 fold and decreased at end stage of disease by 0.2 
fold when compared to WT mice (n=6, * P < 0.05 and ** P < 0.01; Figure 3.4F).  
 
Collectively, the above results suggest that regulation of complement system is perturbed, which 
leads to activation of classical and alternate pathways of complement system in the lumbar spinal 
cord of hSOD1
G93A
 mice, which may contribute to the disease progression of ALS. 
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Figure 3.2: Expression and localisation of C1q in hSOD1
G93A
 and wild-type mice during disease 
progression. (A) mRNA expression profile of C1qB in lumbar spinal cord of hSOD1
G93A
 mice 
relative to wild-type (WT) mice. Dashed line, baseline expression in WT controls at each time 
point. (B) Degree of immunolabelling for C1q significantly increased in the lumbar spinal cord of 
hSOD1
G93A
 mice at end-stage when compared with WT mice. (A, B) Data expressed as mean ± SEM 
(n = 6 mice/group; *P <0.05, **P <0.01, ***P <0.001, Student t test). (C) to (T) Double 
immunolabelling of C1q (red) with cellular markers (green) for motor neurons (ChAT; (C) to (E) 
WT mice, (L) to (N) hSOD1
G93A
 mice), astrocyte (GFAP; (F) to (H) WT mice, (O) to (Q) 
hSOD1
G93A
 mice), and microglia (Iba-1; (I) to (K) WT mice, (R) to (T) hSOD1
G93A
 mice) in the 
ventral lumbar spinal cord of WT and hSOD1
G93A
 mice (end stage). There was minimal expression 
of C1q in WT (C, F and I) with marked increase in hSOD1
G93A
 mice (L, O and R). In hSOD1
G93A
 
mice, C1q was co-localised with ChAT-positive motor neurons (white arrows in (L) and (N) 
(detailed in U)). There was little to no co-localisation of C1q with GFAP-positive astrocytes (Q 
(detailed in V)), and minimal co-localisation with Iba-1-labelled microglia (white arrows in R and 
T (detailed in W)). PS, pre-symptomatic; OS, onset; MS, mid-symptomatic; ES, end-stage. Scale 
bar for all panels = 20 μm. 
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Figure 3.3: Localisation and expression of C3/C3b in hSOD1
G93A
 and wild-type mice during 
disease progression. (A) mRNA expression profile of C3 in lumbar spinal cord of hSOD1
G93A
 mice 
relative to wild-type (WT) mice. Dashed line, baseline expression in WT controls at each time point. 
(B) Degree of immunolabelling for C3b significantly increased in the lumbar spinal cord of 
hSOD1
G93A
 mice at end-stage when compared with WT mice. (A, B) Data expressed as mean ± SEM 
(n = 6 mice/group; *P <0.05, **P <0.01, ***P <0.001, Student t test). (C) to (T) Double 
immunolabelling of C3b (red) with cellular markers (green) for motor neurons (ChAT; (C) to (E) 
WT mice, (L) to (N) hSOD1
G93A
 mice), astrocyte (GFAP; (F) to (H) WT mice, (O) to (Q) for 
hSOD1
G93A
 mice), and microglia (Iba-1; (I) to (K) WT mice, (R) to (T) hSOD1
G93A
 mice) in the 
ventral lumbar spinal cord of WT and hSOD1
G93A
 mice (end stage). C3b immunolabelling was 
absent on motor neurons in WT mice (C to E), but was present on motor neurons in hSOD1
G93A
 
mice (white arrows in L and N (detailed in U)). There was minimal co-localisation of C3b with Iba-
1-labelled microglia in WT (white arrows in I and K). In hSOD1
G93A
 mice immunolabelling of C3b 
was evident in Iba-1-labelled microglia (white arrows, R and T (detailed in W)). There was no co-
localisation with C3b and GFAP-positive astrocytes in WT and hSOD1
G93A
 mice (F to H for WT, O 
to Q (detailed on V) for hSOD1
G93A
 mice). PS, pre-symptomatic; OS, onset; MS, mid-symptomatic 
and ES, end-stage. Scale bars for all panels = 20 μM. 
34 
 
 
Figure 3.4: Altered expression of complement components in hSOD1
G93A
 and wild-type mice at 
different ages of disease progression. (A) mRNA expression of CD55 in the lumbar spinal cord of 
hSOD1
G93A
 transgenic mice relative to age-matched wild-type (WT) mice at four different ages. (B) 
Representative western blot of CD55 with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in 
the lumbar spinal cord of hSOD1
G93A
 mice (SOD1) relative to age-matched WT mice, at different 
ages of disease progression. (C) Protein expression of CD55 determined by semi-quantitative 
densitometry in the lumbar spinal cord of hSOD1
G93A
 mice relative to age-matched WT mice at four 
different ages. (D) to (F) mRNA expressions of C4 (classical pathway, D), factor B (alternative 
pathway, E) and CD59a (regulator, F) in lumbar spinal cord of hSOD1
G93A
 mice relative to age-
matched WT mice at four different ages. (A, C, D, E, F) Dashed lines, baseline expressions in WT 
controls at each time point. Data expressed as mean ± SEM (n = 6 mice/group; *P <0.05, **P 
<0.01, ***P <0.001, Student t test). PS, pre-symptomatic; OS, onset; MS, mid-symptomatic and ES, 
end-stage. 
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3.2.3 C5 is expressed by motor neurons but is not altered in hSOD1
G93A
 mice  
C5a, the ligand for CD88, is rapidly generated from its precursor protein C5 following complement 
activation (Woodruff et al., 2011). We therefore examined the mRNA expression of C5 and protein 
levels of C5a in hSOD1
G93A
 and WT mice by quantitative real time PCR and ELISA respectively. 
C5 mRNA expression levels did not change in hSOD
G93A
 mice when compared to WT mice over 
the four ages examined (Figure 3.5A).  Intriguingly, when we examined the protein expression 
levels of C5a we noted a steady decline in C5a levels with increasing postnatal age in both 
hSOD1
G93A
 and WT mice, however by disease end-stage, the levels of C5a were significantly lower 
in hSOD1
G93A
 mice when compared to WT mice (n=6, * P<0.05; Figure 3.5B).  
Next, we immuno-stained lumbar spinal cords from hSOD1
G93A
 and WT mice for C5 with specific 
cellular markers for motor neurons (anti-ChAT), astrocytes (anti-GFAP), and microglia (anti-
CD11b). C5 was clearly present in ChAT-positive lumbar motor neurons from end-stage 
hSOD1
G93A
 and WT mice (white arrows in Figure 3.5C and 3.5D), but not in GFAP-positive 
astrocytes (Figure 3.5E and 3.5F).  For microglia, we did not see any C5 in CD11b-positive 
microglia in WT spinal cords (Figure 3.5G), but we did see some activated microglia (enlarged cell 
shape with thickening of proximal processes and decrease in ramification of distal branches 
(Raivich, 2005)) expressing low amounts of C5 in the spinal cords from end-stage hSOD1
G93A
 mice 
(white arrows; Figure 3.5H). 
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Figure 3.5: Expression and localisation of C5 and C5a in hSOD1
G93A
 and wild-type mice during 
disease progression. (A) mRNA expression profile of C5 in lumbar spinal cord of hSOD1
G93A
 mice 
relative to wild-type (WT) mice. Dashed line, baseline expression in WT controls at each time 
point. (B) Protein expression of C5a in the lumbar spinal cord of hSOD1
G93A
 mice has decreased by 
end-stage when compared with WT mice. (A, B) Data expressed as mean ± SEM (n = 6 mice/group; 
*P <0.05, Student t test). (C) to (H) Double immunolabelling for C5 (red) with cellular makers 
(green) for motor neurons (ChAT; C and D, arrows), astrocytes (GFAP; E and F), and microglia 
(CD11b; G and H), in the ventral lumbar spinal cord region of hSOD1
G93A
 mice (D, F and H) and 
WT mice (C, E and G) at end-stage. Co-localisation of C5 with these cellular markers is seen as a 
merge of green and red (for example, white arrows in C, D, and H). PS, pre-symptomatic; OS, 
onset; MS, mid-symptomatic; ES, end-stage. Scale bar for C to H = 20μm 
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3.2.4 CD88 is up-regulated during disease progression in hSOD1
G93A
 mice 
Previous studies have shown increase in CD88 expression in multiple rodent models of ALS 
(Woodruff et al., 2008a, Humayun et al., 2009); hence this study aimed to investigate whether there 
were similar differences in expression of CD88 between hSOD1
G93A
 and WT mice during disease 
progression of ALS. 
 
The mRNA expression levels for CD88 in the lumbar spinal cord of hSOD1
G93A
 mice were 
normalised and compared to WT mice during disease progression (30 days to 175 days) using 
quantitative real time PCR. CD88 expression was increased by 2.3 fold at mid-symptomatic, and by 
8.6 fold at end stage of disease respectively, compared with WT mice (n = 6, * P < 0.05and *** P < 
0.001; Figure 3.6A). The protein expression level of CD88 in the lumbar spinal cords of 
hSOD1
G93A
 and WT mice were measured using western blotting. A 45kDa CD88 immuno-reactive 
band was observed in all stages of hSOD1
G93A
 mice and their respective WT mice (Figure 3.6B, 
upper panel). Semi-quantitative densitometry analyses of these bands with respect to GAPDH 
loading controls (Figure 3.6B, lower panel), revealed increased CD88 protein in the lumbar spinal 
cord of hSOD1
G93A
 mice by 2.6 fold and 3.7 fold at mid-symptomatic and end stage respectively, 
when compared to WT mice (n=6, ** P < 0.01 and *** P < 0.001; Figure 3.6C).   
 
3.2.5 CD88 is localised to motor neurons and activated microglia with minimal localisation to 
astrocytes in hSOD1
G93A
 mice 
Next, we aimed to determine the cellular localisation of CD88 that has contributed to the increased 
expression seen in hSOD1
G93A
 mice. To achieve this, we performed immuno-labelling for CD88 on 
lumbar spinal cord sections from hSOD1
G93A
 mice and WT mice. These sections were immuno-
stained for CD88 and with specific cellular markers to identify motor neurons (anti-ChAT), 
microglia (anti-Iba-1) and astrocytes (anti-GFAP).  
 
In WT mice CD88 staining was observed on lumbar motor neurons (Figure 3.6D). CD88-stained 
cells were readily identified as motor neurons due to their large size, location and distinctive 
morphology (Banks et al., 2005). This was confirmed by double labelling with the motor neuron 
marker ChAT (white arrows in Figure 3.6F). CD88 immuno-staining was localized predominantly 
to the motor neurons’ soma (Figure 3.6D to 3.6F). To further support these immuno-histochemical 
findings, we confirmed that motor neurons expressed CD88 mRNA transcripts, by in-situ 
hybridization (Figure 3.6D’, inset). Next, we examined if CD88 immuno-staining was present on 
surrounding microglia and astrocytes in sections of WT lumbar spinal cords. We observed minimal 
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co-localization of CD88 to Iba-1 positive microglia (white arrows in Figure 3.6G and 3.6I), but 
none to GFAP-positive astrocytes (Figure 3.6J to 3.6L).  
 
Following this demonstration of CD88 immuno-labelling in WT lumbar spinal cord, we then 
investigated CD88 cellular localisation in hSOD1
G93A
 mice. CD88 was also expressed on the few 
remaining motor neurons seen at the end-stage of disease (white arrow in Figure 3.6O). By contrast 
to WT lumbar spinal cords, we observed prominent CD88 immuno-staining on other cellular 
structures surrounding motor neurons in the lumbar spinal cords of hSOD1
G93A
 mice by the end-
stage of disease (e.g. yellow arrows in Figure 3.6M and 3.6O). This additional CD88 immuno-
reactivity was investigated in hSOD1
G93A
 end-stage mice, using microglia marker Iba-1 and 
astrocyte marker GFAP. By contrast to Iba-1 positive microglia in WT mice, where these cells 
expressed little observable CD88 and appeared to be non-activated (i.e. small size with slender 
processes; (Raivich, 2005); Figure 3.6H and 3.6I), Iba-1 positive microglia in hSOD1
G93A
 mice 
demonstrated an activated morphology with increased expression of CD88 (white arrows in Figure 
3.6P and 3.6R). As expected, astrocytes were seen to increase in numbers as disease progressed in 
hSOD1
G93A
 mice (Barbeito et al., 2004). This was noted by increased GFAP immuno-labelling in 
the lumbar spinal cord of hSOD1
G93A 
mice at end-stage compared to WT mice (Figure 3.6K-L for 
WT, and Figure 3.6T-U for hSOD1
G93A
 mice). Minimal CD88 co-localisation to GFAP-positive 
astrocytes was observed in WT (Figure 3.6J-L) and at the end-stage of disease in hSOD1
G93A
 mice 
(Figure 3.6S-U).  
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Figure 3.6: Expression and localisation of CD88 in hSOD1
G93A
 and wild-type mice at four 
different ages. (A) mRNA expression of CD88 in the lumbar spinal cord of hSOD1
G93A
 mice 
relative to age-matched wild-type (WT) mice at four different ages. (B) Representative western blot 
of CD88 with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in the lumbar spinal cord of 
hSOD1
G93A
 (SOD1) mice relative to age-matched WT mice at different ages. (C) Protein expression 
of CD88 determined by semi-quantitative densitometry in the lumbar spinal cord of hSOD1
G93A
 
mice relative to age-matched WT mice at four different ages. (A), (C) Dashed lines, baseline 
expression in WT controls at each time point; data expressed as mean ± SEM (n = 6 mice/group; 
*P <0.05, **P <0.01, ***P <0.001, Student t test). (D) to (U) Double immunolabelling of CD88 
(red) with cellular markers (green) for motor neurons (ChAT; (D) to (F) WT mice, (M) to (O) 
hSOD1
G93A
 mice), microglia (Iba-1; (G) to (I) WT mice, (P) to (R) hSOD1
G93A
 mice), and astrocytes 
(GFAP; (J) to (L) WT mice, (S) to (U) for hSOD1
G93A
 mice) in the ventral lumbar spinal cord of 
WT and hSOD1
G93A
 mice at end-stage. CD88 was co-localised with ChAT-positive motor neurons 
(F, O, white arrows). (D)  CD88 mRNA transcript within lumbar motor neurons (determine by 
large cell size and location within the ventral horn). In hSOD1
G93A
 mice, immunolabelling of CD88 
also evident on other cell types, indicated by lack of co-localisation with anti-ChAT (yellow arrows 
in M and O). (G), (I) White arrows, small amount of CD88 staining within nonactivated microglia 
in WT mice, with increased CD88 expression on activated microglia in hSOD1
G93A
 mice (P and R, 
white arrows). PS, pre-symptomatic; OS, onset; MS, mid-symptomatic; ES, end stage. Scale bars 
for all panels = 20 μM. 
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3.3 DISCUSSION 
While the pathogenesis of ALS is still unclear, there is persuasive evidence that complement factors 
are involved in promoting disease progression. Previous studies have demonstrated that C1q and C3 
mRNA expression are significantly increased during ALS progression in hSOD1
G93A
 mice (Lee et 
al., 2012). In addition, up-regulation of CD88 has also been observed in numerous 
neurodegenerative diseases in rodents (Yasojima et al., 1999, Singhrao et al., 1999, Ager et al., 
2010, Woodruff et al., 2006), including ALS (Woodruff et al., 2008a, Humayun et al., 2009), so it is 
plausible to propose that the complement system could be involved in the pathophysiology of ALS. 
The present study demonstrates that components of the classical and alternative complement 
pathways are up-regulated during the course of disease progression in hSOD1
G93A
 mice, and that 
C5a receptor CD88 expression level is also increased. In addition, we found a reduction in two 
major regulatory inhibitors of complement activation as the disease worsened, which is suggestive 
of a progressive dysregulation of complement in this model. Furthermore, we show that C5, the 
precursor of C5a, is expressed predominantly by motor neurons, suggesting that diseased motor 
neurons could be a major source of C5a generation during disease progression. This local 
complement “self-signalling” in the CNS might therefore contribute to motor neuron death in 
hSOD1
G93A
 mice as shown previously for cortical neurons (Pavlovski et al., 2012). Taken together, 
our results indicate that motor neurons may generate C5a under stress, and that this may promote 
self-damage under disease conditions that exist in ALS. 
 
3.3.1 Classical and alternate complement pathways are activated in ALS progression in 
hSOD1
G93A
 mice. 
The present study provided evidence for the activation of classical (C1qB and C4) and alternate 
(factor B) pathways of the complement system in the lumbar spinal cord of hSOD1
G93A
 mice during 
ALS disease progression. This is consistent with numerous studies in mouse models of ALS and 
human patients where increased levels of C1q, C3 and C4 have been found (Lee et al., 2012, Chiu 
et al., 2009). Furthermore this study also extended up-regulation of C1qB and C3 mRNA 
expression in previous studies to protein levels and localisation where C1q and C3b immuno-
labelling was increased in hSOD1
G93A
 mice and expressed on motor neurons and microglia 
compared to WT. This may suggest that up-regulation of these components could assist in the 
removal of dying motor neurons via opsonisation, during disease progression in hSOD1
G93A
 mice. 
 
It is possible that cell fragments or protein aggregates from dying motor neurons could lead to 
complement activation in the degenerating spinal cord (Woodruff et al., 2010). In our study, 
complement activation was seen at disease onset (Postnatal (P) 70 days) and was restricted to the 
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areas of motor neuron death in the spinal cord of hSOD1
G93A
 mice.  Other studies have 
demonstrated that complement components C1q and C3b are located at the neuromuscular junction 
during the early stages of disease (P47) in hSOD1
G93A 
mice (Heurich et al., 2011). These findings 
are consistent with the idea that C1q and C3b may contribute to the cellular destruction of motor 
nerve terminals in these mice (Dupuis and Loeffler, 2009, Cappello et al., 2012, Schafer et al., 
2012). Taken together, these findings and our own are consistent with the hypothesis that the early 
loss of motor neuron terminals is followed by the subsequent death of motor neurons within the 
spinal cord. However, there is current debate about the initiating site of degeneration in the cortical-
motor system (upper motor neurons; (Vucic et al., 2008)) versus peripheral (neuromuscular 
junction; (Dupuis and Loeffler, 2009)). Future studies could contrast complement activation 
temporally at these different sites to determine the initiating site of complement-mediated 
neurodegeneration.  
 
We also showed decreased mRNA expression levels of complement regulators CD55 and CD59a at 
later stages of the disease, which suggests that the homeostasis of the complement system is 
perturbed, which may lead to dysregulation and over-activation of the complement system. This 
supports other studies, which have shown that deficiency in CD55 and CD59a exacerbates neuronal 
degeneration (Wang et al., 2010, Britschgi et al., 2012, Stahel et al., 2009). Our findings are also 
consistent with those of Heurich et al., 2011, where decreased (but non-significant) levels of CD55 
mRNA were observed during the later stages of disease in hSOD1
G93A
 mice. In the present study, 
we also confirmed the mRNA changes in CD55 at the protein level, which similarly showed 
decreased CD55 levels at later stages of disease. Interestingly, we also observed an initial increase 
in the mRNA expression levels of CD55 and CD59a during early stages of disease. This may 
indicate an early negative feedback mechanism to delay the activation of complement in host cells, 
however this needs further investigation. Collectively, our data adds further support to the notion 
that complement activation may play an important role in accelerating motor neuron loss and 
ultimately in progression of ALS.  
 
3.3.2 C5 is expressed by wild-type and hSOD1
G93A
 motor neurons during disease progression. 
C5, the precursor of C5a, is expressed by motor neurons in both wild type and hSOD1
G93A
 mice. 
This suggests that motor neurons are a major source of C5 generation in this tissue. We recently 
showed murine cortical neurons also expressed endogenous C5, and generated C5a in response to 
ischemia, which contributed to neuronal cell death (Pavlovski et al., 2012). It is plausible the same 
phenomenon is occurring in the hSOD1
G93A
 mouse, where stressed and dying motor neurons 
generate their own C5a, to act in an autocrine fashion by binding to CD88, present on these 
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neurons, to promote their death. Indeed, C5a has been suggested to directly cause neuronal cell 
death in a separate model of ALS (Humayun et al., 2009). C5a protein level in the lumbar spinal 
cord only appeared to be significantly decreased by end stage in hSOD1
G93A
 mice when compared 
to wild type mice. This could be due to fewer motor neurons (a source of C5/C5a), and the 
increased CD88 receptor levels by surrounding activated microglia as disease progressed.  
Increased CD88 on these cells would act to internalise and degrade C5a post activation of its 
receptor (Oppermann and Gotze, 1994), which could account for the decline in C5a levels over 
time. The consequence of C5a-CD88 signalling in wild type motor neurons is not yet fully 
understood and will need further investigation. 
 
3.3.3 CD88 is up-regulated during disease progression in hSOD1
G93A
 mice 
The present study provided evidence for a pathophysiological role of CD88 in hSOD1
G93A
 mice. 
Specifically, a significant increase in CD88 protein was observed at mid-symptomatic and end stage 
in hSOD1
G93A
 mice. This is in agreement with our previous studies conducted in hSOD1
G93A
 rats 
(Woodruff et al., 2008a). The increase in CD88 protein in hSOD1
G93A
 mice also parallels 
observations in other models of neurodegenerative diseases, such as Huntington’s disease and 
Alzheimer’s disease (Singhrao et al., 1999, Ager et al., 2010). Taken together, this suggests that 
complement activation is a generalised response to neuronal injury in neurodegenerative diseases. 
Furthermore, the ability of CD88 antagonists to attenuate both neurodegeneration and disease 
progression in rat models of ALS and Huntington’s disease, and in mouse models of Alzheimer’s 
disease, further suggests that increased CD88 activation actively contributes to neurodegeneration 
(Fonseca et al., 2009, Woodruff et al., 2006, Woodruff et al., 2008a). 
 
In addition to an increase in CD88 in hSOD1
G93A
 mice, the present study observed CD88 on motor 
neurons in WT mice, as well as in hSOD1
G93A
 mice. The fact that CD88 was found on WT motor 
neurons suggests that it may play a non-inflammatory role in motor neuron function. Indeed, studies 
including our own, have shown CD88 is also present on other neurons within the brains of WT 
adult mice, including pyramidal neurons in the CA subfields of the hippocampus and neocortex, and 
Purkinje cells in the cerebellum (O'Barr et al., 2001, Crane et al., 2009); and CD88 has also been 
documented to be expressed on human motor neurons (Humayun et al., 2009). Hence the 
physiological significance of C5a receptor presence in motor neurons awaits further study. 
 
Previous studies have shown that motor neuron death in animal models of ALS is exacerbated by 
toxic signals emanating from non-neuronal neighbouring cells (astrocytes and microglia), via an 
inflammatory response that accelerates disease progression (Kreutzberg, 1996, Nagai et al., 2007). 
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The present study also showed up regulation of CD88 on activated microglia, but minimal 
expression on astrocytes in hSOD1
G93A
 mice. The latter is in contrast to our previous study 
conducted in hSOD1
G93A
 rats, where CD88 was expressed primarily on proliferating astrocytes 
(Woodruff et al., 2008a), but is in support of other studies, which show CD88 on microglia in other 
neurodegenerative diseases (Griffin et al., 2007, Ager et al., 2010). The differential expression of 
CD88 on these proliferating glial cells between hSOD1
G93A
 rat and mouse models, may suggest a 
differential role for CD88 in these two species.   
 
The strong co-localisation of CD88 with activated microglia in hSOD1
G93A
 mice suggests that 
CD88-activated microglia contribute to the propagation of disease as opposed to the aetiology of the 
disease. This is supported by previous studies where transplanted wild type microglia produced no 
delay of disease onset but survival was greatly extended through slowing of disease progression in 
hSOD1
G93A
 mice (Beers et al., 2006). The exact mechanism by which C5a-CD88 signalling in 
microglia plays a role in neuro-degeneration is still unknown, but may involve the release of 
reactive oxygen species through NADPH oxidase, or pro-inflammatory cytokine, which have been 
shown to be up-regulated in ALS (Wu et al., 2006). 
 
3.4 CONCLUSION 
In summary, the present study has demonstrated the up-regulation of classical and alternative 
pathway complement components, together with decreased levels of complement regulators, 
suggesting that complement activation and/or its dysregulation may play an important role in motor 
neuron loss and ultimately in progression of ALS. Expression of C5a receptor, CD88 was up-
regulated in hSOD1
G93A
 mice, and the increased expression of CD88 in end-stage hSOD1
G93A
 mice 
appears to be due to increased microglial CD88 expression. Taken together, these results indicate 
that CD88 may play important role in the pathophysiology of ALS. These results pave the way for 
preliminary pharmacological experiments using specific downstream complement inhibitors in 
hSOD1
G93A
 mice, such as C5 inhibitors or antagonists to C5a receptor that could conceivably be 
extended to humans with positive therapeutic outcomes. 
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CHAPTER 4 
“Complement factor C5a and its receptor CD88 contributes to the pathology in a mouse 
model of Amyotrophic lateral sclerosis” 
* Part of this chapter was published in the Proceeding of the National Academy of Sciences of 
the United States of America - Woodruff, Trent M., Lee, John D. and Noakes, Peter G. (2014) 
Role for terminal complement activation in amyotrophic lateral sclerosis disease progression. 
Proceeding of the National Academy of Sciences of the United States of America, 111 1: E3-E4 
4.1 INTRODUCTION 
As discussed in previous chapters, complement activation has long been implicated in the 
pathogenesis of Amyotrophic lateral sclerosis (ALS), with numerous clinical and animal studies 
demonstrating strong up-regulation of activation fragments of complement components C1q, C3 
and C4 in the serum, cerebrospinal fluid and neurological tissue (including spinal cord and motor 
cortex) of ALS patients and animal models of ALS (Lee et al., 2012). Intriguingly, recent studies 
have shown deletion of C1q, C3 and C4 in hSOD1 transgenic mouse models did not show any 
beneficial effects on the disease progression of ALS (Chiu et al., 2009, Lobsiger et al., 2013).  
Hence, these studies indicate that blocking upstream activation pathways of complement does not 
alter the disease course in hSOD1 transgenic mice. In contrast to these studies, our laboratories have 
previously shown that chronic administration of a specific C5a receptor CD88 antagonist PMX205 
in hSOD1
G93A
 transgenic rats markedly delayed the onset of motor symptoms and increased 
survival, compared to untreated animals (Woodruff et al., 2008a). Further, data presented in Chapter 
3 demonstrated up-regulation of CD88 in the lumbar spinal cord of hSOD1
G93A
 transgenic mice as 
disease progressed, suggesting that C5a-CD88 signalling may have a pathogenic role in the disease 
progression of ALS (Lee et al., 2013). 
 
In the present study, we examined the effect of selective CD88 antagonist PMX205 on the disease 
progression of ALS in hSOD1
G93A
 mice. Chronic oral administration of PMX205 to hSOD1
G93A
 
mice significantly improved hind-limb grip strength, slowed disease progression and extended 
survival. Additionally, we have also confirmed that hSOD1
G93A
 mice lacking CD88 (hSOD1
G93A
 x 
CD88
-/-
) have a similarly extended survival. hSOD1
G93A
 x CD88
-/-
 mice also showed reductions in 
microglia and cytokine mRNA levels when compared to hSOD1
G93A
 mice. These results indicate 
that downstream (terminal pathway) complement activation, leading to increased expression of 
CD88 in the hSOD1
G93A
 mice has an important role in motor neuron death and contributes to the 
pathology in the hSOD1
G93A
 mice. 
45 
 
4.2 RESULTS 
4.2.1 Treatment with CD88 antagonist extends survival, improves hind-limb grip strength and 
slows disease progression in hSOD1
G93A
 mice in a concentration dependent manner. 
Previous studies have shown increase in CD88 expression in multiple rodent models of ALS 
(Woodruff et al., 2008a, Humayun et al., 2009, Lee et al., 2013); hence this study aimed to elucidate 
whether the up-regulation of CD88 in the lumbar spinal cord of hSOD1
G93A
 mice were contributing 
to disease progression. hSOD1
G93A
 mice were orally dosed with the selective CD88 antagonist 
PMX205 beginning from 35 days of age with two different concentrations (3mg/kg/day and 
9mg/kg/day). These concentrations were chosen based on previous reports of efficacy in a mouse 
transgenic model of Alzheimer’s disease (3mg/kg; (Fonseca et al., 2009)), and inflammatory bowel 
disease (9 mg/kg; (Jain et al., 2013)). The end-stage of disease (survival time) in these animals was 
determined as complete hind-limb paralysis and an inability to right itself once placed on its back 
(Ludolph et al., 2007). 
 
We first performed preliminary experiments in a small cohort of mice treated with PMX205 at 
3mg/kg/day. PMX205 treatment at this lower dose did not affect survival time when compared with 
vehicle treated hSOD1
G93A
 mice (mean end stage of disease, vehicle = 170.6 ± 2.2 days and 
PMX205 = 174.5 ± 3.4 days, n = 5 – 6, P = 0.8897; Figure 4.1A). Decline in neuromotor 
performance was also assessed in these animals using body weight and hind-limb grip strength as it 
is a more sensitive measure of detecting motor deficit symptoms in hSOD1
G93A
 mice compared to 
rota-rod performance (Lee et al., 2013). There was no significant difference in body weight 
alterations between vehicle and PMX205 treated hSOD1
G93A
 mice (n = 5 – 6, P > 0.05; Figure 
4.1B). Next we measured the maximal hind-limb grip strength as a measure of motor deficit 
symptoms in these animals. PMX205 treated hSOD1
G93A
 mice did not show any difference in 
maximal hind-limb grip strength when compared to vehicle treated hSOD1
G93A
 mice (n = 5 – 6, P > 
0.05; Figure 4.1C). The overall disease progression was also determined by age at which the 
maximal grip strength declined by 25, 50, 75 and 100%. Vehicle treated hSOD1
G93A
 mice showed 
similar ages for decline in grip strength when compared to PMX205 treated hSOD1
G93A
 mice (n = 5 
– 6, P = 0.5461; Figure 4.1D). Intriguingly, these preliminary experiments suggested that PMX205 
treatment at 3mg/kg/day did not improve ALS pathology in hSOD1
G93A
 mice, despite being used at 
a similar dose to that previously reported in a transgenic mouse model of Alzheimer’s disease. 
However, a separate study recently reported that an increased dose of 200µg/day (~8mg/kg/day) 
PMX205 is required to achieve efficacy in a mouse model of inflammatory bowel disease (Jain et 
al., 2013). Thus, for the next series of experiments, we decided to repeat our study with a higher 
dose of PMX205, choosing to dose at a 3-fold higher concentration of 9mg/kg/day. 
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Figure 4.1: “Pre-Onset” PMX205 treatment at 3mg/kg/day does not affect survival, weight, hind-
limb grip strength and disease progression in hSOD1
G93A
 transgenic mice. hSOD1
G93A
 mice were 
orally dosed with the selective CD88 antagonist PMX205 at 35 days of age (3mg/kg/day). A shows 
a Kaplan-Meier plot of ages (in days) in which hSOD1
G93A
 mice were treated with dH2O (vehicle; 
orange line) or PMX205 (blue line) reached end-stage of disease (complete hind-limb paralysis and 
an inability to right itself once placed on its back; n = 5 -6, P = 0.8897, log-rank test). PMX205 
treatment at 35 days of age (3mg/kg/day) did not show alterations in survival of these animals. B 
and C shows no difference in weight and hind-limb grip strength between vehicle (orange line) and 
PMX205 (blue line) treated hSOD1
G93A
 mice (n = 5 – 6, P > 0.05, student t-test). D shows no 
difference in disease progression (determined by age at which maximal grip strength decline at 25, 
50, 75 and 100%) between hSOD1
G93A
 mice treated with vehicle (orange bar) and PMX205 (blue 
bar) (n = 5 -6, P = 0.5461, student t-test). Data expressed as mean ± SEM.  
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PMX205 treatment of hSOD1
G93A
 mice at 9mg/kg/day resulted in a significant extension in survival 
time when compared with vehicle treated hSOD1
G93A
 mice (mean end stage of disease, vehicle = 
162.8 ± 3.2 days and PMX205 = 173.5 ± 3.2 days, n = 12 – 13, P < 0.05; Figure 4.2A). The weight 
of vehicle and PMX205 treated hSOD1
G93A
 mice both reached the maximum at 126 days of age, 
however there was no difference in body weight between vehicle and PMX205 treated hSOD1
G93A
 
mice (n = 12 – 13, P > 0.05; Figure 4.2B). Although there was no difference in body weight, 
PMX205 treatment improved the hind-limb grip strength at 105 days of age (n = 12 – 13, * P < 
0.05, + P < 0.01; Figure 4.2C). PMX205 treatment also significantly slowed the disease 
progression as the age at which it reached 25, 50, 75 and 100% decline in maximal grip strength 
was delayed (n = 12 – 13, * P < 0.05, ** P < 0.01, Figure 4.2D). 
 
Finally, to confirm that CD88 is a valid therapeutic target in ALS, we also generated hSOD1
G93A
 
mice lacking CD88, by crossing hSOD1
G93A
 mice with CD88
-/-
 mice (hSOD1
G93A
 x CD88
-/-
). These 
hSOD1
G93A
 x CD88
-/-
 showed a similarly extended survival to PMX205 treated hSOD1
G93A
 mice 
when compared to hSOD1
G93A
 mice (mean end stage of disease, hSOD1
G93A
 = 168.2 ± 1.6 days and 
hSOD1
G93A
 x CD88
-/-
 = 176.1 ± 2.1 days, n = 24, P < 0.01; Figure 4.3A). 
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Figure 4.2: “Pre-Onset” PMX205 treatment at 9mg/kg/day extends survival, improves hind-limb 
grip strength and slows disease progression in hSOD1
G93A
 transgenic mice. hSOD1
G93A
 mice were 
orally dosed with the selective CD88 antagonist PMX205 at 35 days of age (9mg/kg/day). A shows 
a Kaplan-Meier plot of ages (in days) in which hSOD1
G93A
 mice were treated with dH2O (vehicle; 
orange line) or PMX205 (blue line) reached end-stage of disease (complete hind-limb paralysis and 
an inability to right itself once placed on its back; n = 12 – 13, P < 0.05, log-rank test). PMX205 
treatment at 35 days of age (9mg/kg/day) resulted in significant extension in survival time 
compared with vehicle treatment. B shows no difference in weight between vehicle (orange line) 
and PMX205 (blue line) treated hSOD1
G93A
 mice (n = 12 – 13, P > 0.05, student t-test). C shows 
significant improvement  in hind-limb grip strength for PMX205 treated versus vehicle treated 
hSOD1
G93A
 mice at 105 days of age (n = 12 – 13, * P<0.05, + P<0.01, student t-test). D shows 
slowed disease progression (determined by age at which maximal grip strength decline at 25, 50, 
75 and 100%) in hSOD1
G93A
 mice treated with PMX205(blue bar) when compared with vehicle 
treated hSOD1
G93A
 mice (orange bar) at 25, 50, 75 and 100% decline in maximal grip strength (n = 
12 – 13, * P < 0.05, ** P < 0.01, student t-test). hSOD1G93A mice lacking C5a signaling via CD88  
shows a significant extension in survival, improved hind-limb grip strength and slowed disease 
progression, demonstrating a pathogenic role for C5a in this mutant ALS mouse model. Data 
expressed as mean ± SEM.  
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Figure 4.3: The C5a receptor CD88 contributes to disease progression in the hSOD1
G93A
 genetic 
model of ALS. A shows a Kaplan-Meier plot of ages (in days) in which hSOD1
G93A
 mice with 
normal (CD88
+/+
, orange line) or fully deleted (CD88
-/-
, blue line) CD88 reached end-stage of 
disease (complete hind-limb paralysis and an inability to right itself once placed on its back; n = 
24, P < 0.01, log-rank test). hSOD1
G93A
 mice lacking CD88 showed a similarly extended survival to 
PMX205 treated hSOD1
G93A
 mice. Data expressed as mean ± SEM. 
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4.2.2 Post-Onset treatment with CD88 antagonist does not affect motor performance but 
extends survival and slows disease progression in hSOD1
G93A
 mice.  
We next aimed to determine if CD88 inhibition at a later stage of disease could still reduce ALS 
pathology in hSOD1
G93A
 mice. This is important, as ALS patients generally present in the clinic 
with manifest disease, where motor neuron loss has already progressed. Thus, this experiment 
provides a scenario which would more closely model a therapeutic intervention for human ALS 
patients. hSOD1
G93A
 mice were therefore orally dosed with PMX205 at 91 days of age with the 
efficacious dose of 9mg/kg/day. As shown in Chapter 3, 91 days is the age at which there is already 
considerable motor decline, and motor neuron loss. PMX205 treatment in hSOD1
G93A
 mice from 
this post-onset disease age showed an increase in survival time when compared to vehicle treated 
hSOD1
G93A
 mice (mean end stage of disease, vehicle = 169.2 ± 2.8 days and PMX205 = 179.7 ± 1.8 
days, n = 9, P < 0.01; Figure 4.4A). However post-onset PMX205 treatment did not affect the body 
weight and hind-limb grip strength of hSOD1
G93A
 mice when compared to vehicle treatment (n = 9, 
P > 0.05; Figure 4.4B and 4.4C). Importantly though, PMX205 treatment significantly slowed 
disease progression at the later stages of disease as the age at which it reached 75 and 100% decline 
in maximal grip strength was delayed (n = 9, * P < 0.05, Figure 4.4D). This demonstrates that 
treatment of ALS mice with PMX205, well into their disease progression, can still have therapeutic 
benefits. 
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Figure 4.4: “Post-Onset” PMX205 treatment at 9mg/kg/day does not affect motor performance 
but extends survival and slows disease progression at later stages in hSOD1
G93A
 transgenic mice. 
hSOD1
G93A
 mice were orally dosed with the selective CD88 antagonist PMX205 at 91 days of age 
(9mg/kg/day). A shows a Kaplan-Meier plot of ages (in days) in which hSOD1
G93A
 mice treated 
with dH2O (vehicle; orange line) or PMX205 (blue line) reached end-stage of disease (complete 
hind-limb paralysis and an inability to right itself once placed on its back; n = 9, P < 0.01, log-
rank test). PMX205 treatment at 91 days of age (9mg/kg/day) resulted in significant extension in 
survival time compared with vehicle treatment. B and C shows no difference in weight and hind-
limb grip strength between vehicle (orange line) and PMX205 (blue line) treated hSOD1
G93A
 mice 
(n = 9, P > 0.05, student t-test). D shows slowed disease progression (determined by age at which 
maximal grip strength decline at 25, 50, 75 and 100%) in hSOD1
G93A
 mice treated with PMX205 
(blue bar) when compared to vehicle treated hSOD1
G93A
 mice (orange bar) at 75% and 100% 
decline in maximal grip strength (n = 9, * P < 0.05, student t-test). Data expressed as mean ± SEM.  
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4.2.3 hSOD1
G93A
 mice lacking CD88 have reduced microglia and monocyte mRNA levels 
when compared to hSOD1
G93A
 mice at end-stage of disease progression. 
We next aimed to identify some of the underlying mechanisms for protection from pathology in 
mice treated with PMX205, or deficient in CD88. Since the studies described above used PMX205-
treated mice which were taken to end-stage of disease, we decided to use hSOD1
G93A
 x CD88
-/-
 for 
these experiments. This allowed us to collect tissue from animals at different ages throughout 
disease progression. Importantly, inhibition of CD88 using PMX205 (pharmacological approach) or 
hSOD1
G93A
 mice lacking CD88 (genetic approach) showed similarly extended survival when 
compared to vehicle and hSOD1
G93A
 mice, validating this approach. Given our previous 
experiments demonstrating marked CD88 accumulation in activated microglia in hSOD1
G93A
 mice 
(Chapter 3), we focussed our attention on glial activation markers, and their downstream activation 
products. CD88 activation is known to have generally pro-inflammatory functions on microglia 
(Woodruff et al., 2010) and microglia activation is known to contribute to ALS pathology (Chiu et 
al., 2013). 
 
We first investigated whether the absence of CD88 in hSOD1
G93A
 mice had any effect on 
astrocytosis and microgliosis in the lumbar spinal cord. mRNA expression levels of GFAP (marker 
of astrocytes), Iba-1 (marker of both resident microglia and infiltrating monocyte/macrophages), 
Entpd1 (CD39; predominant marker of resident microglia) and Ly6C (predominant marker of early 
infiltrating monocyte/macrophages) were measured in the lumbar spinal cord of hSOD1
G93A
 mice 
and hSOD1
G93A
 x CD88
-/-
 mice at mid-symptomatic and end-stage of disease progression using 
quantitative real time PCR. GFAP transcripts were unaltered in hSOD1
G93A
 x CD88
-/-
 mice at mid-
symptomatic and end-stage of disease when compared to hSOD1
G93A
 mice (n = 6, P > 0.05; Figure 
4.5A), in line with the lack of expression of CD88 on astrocytes (Chapter 3). Iba-1 transcripts 
however, were significantly reduced in hSOD1
G93A
 x CD88
-/-
 mice by 0.37 fold at end-stage of 
disease when compared to hSOD1
G93A
 mice respectively (n = 6, ** P < 0.01; Figure 4.5B). Entpd1 
mRNA expression was initially increased in hSOD1
G93A
 x CD88
-/-
 mice by 0.6 fold at mid-
symptomatic, and decreased at end-stage of disease by 0.34 fold when compared to hSOD1
G93A
 
mice (n = 6, * P < 0.05, *** P < 0.001; Figure 4.5C). Ly6C mRNA was also decreased at end-
stage by 0.24 fold when compared to hSOD1
G93A
 mice (n = 6, * P < 0.05; Figure 4.5D). 
 
4.2.4 hSOD1
G93A
 mice lacking CD88 have reduced cytokine tumour necrosis factor α and 
interleukin-1β levels when compared to hSOD1G93A mice at end-stage of disease progression. 
Activation of CD88 also induces synthesis of cytokines to modulate inflammatory processes, and 
has been shown to induce cytokine expression in microglia (Woodruff et al., 2010). Importantly, 
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pro-inflammatory cytokine such as tumour necrosis factor α (TNFα) and interleukin-1β (IL-1β) are 
thought to propagate disease progression in ALS (Elliott, 2001, Nguyen et al., 2001, Hensley et al., 
2003). Hence we investigated whether the absence of CD88 in hSOD1
G93A
 mice had any effect on 
the cytokine TNFα and IL-1β levels in the lumbar spinal cord. mRNA expression of TNFα and IL-
1β were measured in the lumbar spinal cord of hSOD1G93A mice and hSOD1G93A x CD88-/- mice at 
mid-symptomatic and end-stage of disease progression using quantitative real time PCR. TNFα 
transcripts were significantly reduced in hSOD1
G93A
 x CD88
-/-
 mice by 0.38 fold at end-stage of 
disease when compared to hSOD1
G93A
 mice (n = 6, *** P < 0.001; Figure 4.6A). IL-1β mRNA 
expression was also decreased in hSOD1
G93A
 x CD88
-/-
 mice by 0.52 fold at end-stage of disease 
when compared to hSOD1
G93A
 mice (n = 6, *** P < 0.001; Figure 4.6B). 
 
 
 
 
Figure 4.5: hSOD1
G93A
 mice lacking CD88 have reduced microglia and monocyte mRNA levels 
when compared with hSOD1
G93A
 mice at end-stage of disease progression. (A) to (D) mRNA 
expressions of GFAP (astrocytes, A), Iba-1 (microglia/monocyte, B), Entpd1 (CD39; microglia, C) 
and Ly6C (monocyte, D) in lumbar spinal cord of hSOD1
G93A
 mice relative to age-matched 
hSOD1
G93A 
 mice lacking CD88 (hSOD1
G93A
 x CD88
-/-
) at mid-symptomatic and end-stage of 
disease progression. Data expressed as mean ± SEM (n = 6 mice/group; *P <0.05, **P <0.01, 
***P <0.001, Student t test). MS, mid-symptomatic = 130 days postnatal (P130); ES, end-stage = 
175 days postnatal (P175). 
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Figure 4.6: hSOD1
G93A
 mice lacking CD88 have reduced cytokine tumour necrosis factor α and 
interleukin-1β mRNA levels when compared with hSOD1G93A mice at end-stage of disease 
progression. (A) mRNA expression of TNFα in the lumbar spinal cord of hSOD1G93A mice relative 
to age-matched hSOD1
G93A 
mice lacking CD88 (hSOD1
G93A
 x CD88
-/-
) at mid-symptomatic and 
end-stage of disease progression. (B) mRNA expression of IL-1β in the lumbar spinal cord of 
hSOD1
G93A
 mice relative to age-matched hSOD1
G93A
 x CD88
-/- 
at mid-symptomatic and end-stage of 
disease progression. Data expressed as mean ± SEM (n = 6 mice/group; ***P <0.001, Student t 
test). MS, mid-symptomatic = 130 days postnatal (P130); ES, end-stage = 175 days postnatal 
(P175). 
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4.3 DISCUSSION  
Currently there is no effective treatment for ALS. Although the pathogenesis of ALS is still unclear, 
there is convincing evidence that complement factors are involved in promoting disease 
progression. Previous studies have demonstrated that C1q, C3 and C4 mRNA expression are 
significantly increased during ALS progression in hSOD1
G93A
 mice. However, given that deletion 
of C1q, C3 and C4 in hSOD1 transgenic mouse models did not show any beneficial effects on the 
disease progression of ALS, it indicates that blocking upstream complement activation pathways 
does not contribute to ALS mice neurotoxicity. Hence, it is possible instead, that downstream 
complement factors, potentially generated by the fourth “extrinsic pathway”, may play a role in the 
disease progression of ALS. In support of this finding, we have shown that chronic administration 
of a specific CD88 antagonist PMX205 in hSOD1
G93A
 transgenic rats have markedly delayed the 
onset of motor symptoms and increased survival, compared to untreated animals (Woodruff et al., 
2008a). In addition, up-regulation of CD88 has also been observed in numerous neurodegenerative 
diseases in rodents (Yasojima et al., 1999, Singhrao et al., 1999, Ager et al., 2010, Woodruff et al., 
2006), including ALS (Woodruff et al., 2008a, Humayun et al., 2009), so it is plausible to propose 
that downstream complement C5a-CD88 signalling may have a pathogenic role in the disease 
progression of ALS (Lee et al., 2013).  
 
The present study demonstrates that inhibition of CD88 using oral administration of a specific 
CD88 antagonist significantly improved hind-limb grip strength, slowed disease progression and 
extended survival in the most commonly used model of ALS (hSOD1
G93A
 mice). Additionally, 
inhibition of CD88 using hSOD1
G93A
 x CD88
-/-
 mice also showed similarly extended survival. 
Furthermore, I showed that hSOD1
G93A
 x CD88
-/-
 mice also showed reductions in microglia, 
monocytes and cytokine mRNA levels when compared to hSOD1
G93A
 mice. Taken together these 
results indicate that CD88 activation in hSOD1
G93A
 mice actively contributes to the pathogenesis of 
ALS, potentially through over-activation of reactive microglia. 
 
4.3.1 Treatment with CD88 antagonist improves motor function, slows disease progression 
and extends survival time 
The present study provided evidence for a pathophysiological role of CD88 in hSOD1
G93A
 
transgenic mice. Specifically, we inhibited CD88 activation with the CD88 selective antagonist 
PMX205. This orally active compound crosses the blood-brain barrier and has been shown to have 
a protective effect in multiple models of neurodegenerative diseases such as Huntington’s disease 
and Alzheimer’s disease (Woodruff et al., 2006, Fonseca et al., 2009). In our preliminary 
experiments, treatment with PMX205 at concentration of 3mg/kg/day did not extend survival time, 
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improve motor performance or slow disease progression in hSOD1
G93A
 mice in contrast to its 
protective effect in other neurodegenerative diseases, suggesting that the concentration of PMX205 
used was not optimal in hSOD1
G93A
 mice. Indeed, a recent study by our colleagues demonstrated 
that an 8mg/kg/day oral dose was required to achieve efficacy in a mouse model of inflammatory 
bowel disease; a 4mg/kg/day dose was without effect (Jain et al., 2013). Hence I also dosed ALS 
mice with PMX205 at a higher concentration of 9mg/kg/day and our results were striking. PMX205 
treatment of hSOD1
G93A
 mice at 9mg/kg/day resulted in a significant extension in survival time, 
improved hind-limb grip strength and slowed disease progression. This is in agreement with our 
previous studies conducted in hSOD1
G93A
 transgenic rats where it was shown PMX205 significantly 
extended survival time and delayed the onset of motor dysfunction. Our result was also confirmed 
with hSOD1
G93A
 x CD88
-/-
 mice as these mice showed similarly extended survival when compared 
to hSOD1
G93A
 mice. Taken together this suggests that increased CD88 activation in hSOD1
G93A
 
mice actively contributes to the pathogenesis seen in this model of ALS. These findings also 
demonstrate that optimal selection of PMX205 dosing is required to achieve efficacy. There are 
previous reports of a lack of efficacy with PMX205 in a hSOD1 mouse model of ALS (Klos et al., 
2013), and based on our current findings, this may be due to an inadequate dose of PMX205 used 
(P. Monk personal communication). The reasons why a higher dose of PMX205 was required in our 
ALS studies, whereas a lower (~2mg/kg/day) dose was required in a transgenic mouse model of 
Alzheimer’s disease is unknown (Fonseca et al., 2009). However, importantly, it should be noted 
that these 2 models use distinctly different strains of mice, which might explain these differences. 
We are currently performing pharmacokinetic studies to quantify the concentrations of PMX205 in 
the brain after oral dosing, and to correlate this with efficacy, in order to optimise therapeutic 
dosing of PMX205 in future studies. 
 
Our drug treated experiments included hSOD1
G93A
 mice dosed from very early age (Day 35) to 
determine the maximum effect of CD88 inhibition, as well as at a later point after the onset of 
motor deficits (Day 91). Our results showed that there was no significant difference in survival time 
extension between the two dosing groups, suggesting that the pathogenic involvement of C5a 
occurs subsequent to day 91. This is in agreement with our previous experiments showing up-
regulation of CD88 at 130 and 175 days in hSOD1
G93A
 mice, indicating that C5a exacerbates 
disease pathology but does not initiate the onset of disease (Lee et al., 2013). Although there was no 
difference in survival time extension between the two dosing groups, hSOD1
G93A
 mice treated post 
onset of motor deficit did not show improved hind-limb grip strength but delayed age reaching 75% 
and 100% decline in their maximal grip strength (i.e. slowed disease progression). The onset of 
motor deficit measured by hind-limb grip strength is 70 days in hSOD1
G93A
 mice which also 
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correlates with the decline in motor neuron numbers (Lee et al., 2013). Hence treating these animals 
at Day 91 when there is significant decline in motor neuron numbers would be expected to only 
show minimal improvement in motor functions.  
 
4.3.2 Reduced microglia/monocytes and cytokine levels in hSOD1
G93A
 mice lacking CD88 
Many studies have shown that motor neuron death in ALS animal models is exacerbated by toxic 
signals emanating from non-neuronal neighbouring cells (astrocytes and microglia); via an 
inflammatory response that accelerates disease progression (Kreutzberg, 1996, Nagai et al., 2007). 
Our previous study showed strong co-localisation of CD88 to microglia and minimal co-localisation 
of CD88 to astrocytes in hSOD1
G93A
 transgenic mice. Hence to elucidate the mechanism of C5a-
CD88 signalling in microglia in the disease progression of ALS, we investigated whether the 
absence of CD88 in hSOD1
G93A
 mice had any effect on astrocytosis and microgliosis. We showed 
that there was no difference in astrocyte mRNA levels between hSOD1
G93A
 and hSOD1
G93A
 x 
CD88
-/-
 mice while there was a significant reduction in microglia mRNA levels (Iba-1 and CD39) in 
hSOD1
G93A
 x CD88
-/-
 mice. This suggests that at least some of the therapeutic benefits seen with 
CD88 antagonism could be due to the reduction of C5a-mediated activation of microglia. In 
addition to microglia, we have also demonstrated that hSOD1
G93A
 x CD88
-/-
 mice has decreased 
levels of inflammatory monocytes. This supports recent studies where they have shown that using 
anti-Ly6C mAb in hSOD1
G93A
 mice slowed disease progression and attenuated neuronal damage by 
decreasing infiltration of Ly6C-positive monocytes to the spinal cord (Butovsky et al., 2012). This 
suggests that C5a-CD88 signalling may play a role in recruiting inflammatory monocytes into the 
lumbar spinal cord that contributes to the pathogenesis of ALS. 
 
Microglia are a well-known contributor to the pathology observed in hSOD1 mouse models of ALS 
(Henkel et al., 2009). Microglia derived from hSOD1-transgenic mice release reactive oxygen 
species and cytokine that induce motor neuron cell death (Wu et al., 2006, Tonges et al., 2014, 
Beers et al., 2008, Hensley et al., 2002, Alexianu et al., 2001). Several studies have shown that 
expression of pro-inflammatory cytokines such as TNFα and IL-1β is an early event in hSOD1 
mouse models of ALS and promotes disease progression (Elliott, 2001, Nguyen et al., 2001, 
Hensley et al., 2003). We show here that there is a reduction in both TNFα and IL-1β in the lumbar 
spinal cord of hSOD1
G93A
 x CD88
-/-
 mice when compared to hSOD1
G93A
 mice. This suggests that 
lack of C5a-CD88 signalling in the microglia reduces cytokine levels, ultimately leading to reduced 
inflammation which attenuates disease pathogenesis in this model of ALS. Our findings are also 
consistent with those of Meissner et al., 2010, where they showed extended survival and slowed 
disease progression in hSOD1
G93A
 mice lacking IL-1β (Meissner et al., 2010). Unexpectedly, there 
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is a conflicting literature on the neurotoxic effect of TNFα in hSOD1G93A mice as they reported that 
disruption of TNFα in hSOD1G93A mice failed to influence survival or progression of disease 
(Gowing et al., 2006). However, an increase in transcripts encoding for IL-1β was observed in these 
animals. Hence suggesting that up-regulation of IL-1β may be part of a compensatory process 
(Gowing et al., 2006). Importantly, C5a-CD88 signalling can inhibit the release of both pro-
inflammatory cytokine TNFα and IL-1β, which would likely contribute to the disease progression 
of ALS.  
 
4.4 CONCLUSION 
In summary, the present study has demonstrated that inhibition of CD88 using oral administration 
of a specific CD88 antagonist significantly improved hind-limb grip strength, slowed disease 
progression and extended survival. Additionally, inhibition of CD88 using hSOD1
G93A
 x CD88
-/-
 
mice also showed similarly extended survival, suggesting that C5a-CD88 signalling in these 
animals contributes to motor neuron death and ultimately disease progression of ALS. Expression 
of microglia, monocytes and cytokine (TNFα and IL-1β) transcripts was also reduced in hSOD1G93A 
x CD88
-/-
 mice. Taken together these results indicate that inhibition of CD88 significantly 
attenuates disease progression potentially by reducing levels of microglia, monocytes and cytokines 
which all have an important role in motor neuron death and contributes to the pathology in the 
hSOD1
G93A
 mice. Specifically, our studies suggest that inhibiting the pro-inflammatory C5 
activation fragment, C5a, which is central to, and generated by, all complement pathways, may be 
an important therapeutic strategy to treat ALS. 
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CHAPTER 5 
“Absence of C3a-C3aR signalling worsens disease pathology in a mouse model of 
Amyotrophic lateral sclerosis” 
 
5.1 INTRODUCTION 
Many studies including our own have shown that complement activation is involved in the 
pathogenesis of Amyotrophic lateral sclerosis (ALS) (Chapters 3, 4). However, recent studies have 
shown that inhibition of upstream complement components C1q, C3 and C4 in hSOD1 transgenic 
mouse models did not show any beneficial effects on the disease progression of ALS (Chiu et al., 
2009, Lobsiger et al., 2013). Hence, these combined studies indicate that blocking upstream 
complement activation pathways does not alter the disease course in hSOD1 transgenic mice. 
However, it introduces the new possibility that downstream complement factors, potentially 
generated by the fourth “extrinsic pathway”, may play a role in the disease progression of ALS 
(Woodruff et al., 2014).  
 
Complement activation triggers the generation of cleavage products, including the complement 
peptides C3a and C5a (Klos et al., 2013). C5a-CD88 signalling has been studied extensively to 
show a pathogenic role in the disease progression of ALS by inducing chemotaxis and activation of 
microglia, with subsequent release of pro-inflammatory cytokine tumour necrosis factor α (TNFα) 
and interleukin-1β (IL-1β) as mentioned in chapter 4 (Woodruff et al., 2014). By contrast to C5a, 
the biological action of C3a in the disease progression of ALS has never been studied. Although 
less work has been done with C3a, several studies have suggested that C3a-C3aR signalling could 
have several protective roles in the central nervous system diseases as mentioned in chapter 1 
(Yanamadala and Friedlander, 2010). 
 
In the present study, we examined the expression and cellular location of central component C3 and 
its receptor C3aR during disease progression. We also examined the effect of C3aR deletion on the 
disease progression of ALS using hSOD1
G93A
 mice lacking C3aR (hSOD1
G93A
 x C3aR
-/-
). 
hSOD1
G93A
 x C3aR
-/-
 mice had significantly reduced hind-limb grip strength and body weight. 
These mice also had accelerated disease progression and shortened survival time. hSOD1
G93A
 x 
C3aR
-/-
 mice also showed up-regulation of astrocytes and microglia mRNA levels but down-
regulation of monocyte mRNA level. hSOD1
G93A
 x C3aR
-/-
 mice also showed no change in cytokine 
levels when compared to hSOD1
G93A
 mice. These results suggest a novel neuroprotective role for 
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C3aR in hSOD1
G93A
 mice and identify C3aR up-regulation or activation as a novel target to slow 
down the progression of disease progression in ALS patients. 
 
5.2 RESULTS 
5.2.1 C3 and C3aR are up-regulated during disease progression in hSOD1
G93A
 mice 
The mRNA expression levels for C3 and C3aR in the lumbar spinal cord of hSOD1
G93A
 mice were 
normalised and compared to wild-type (WT) mice during disease progression (30 days to 175 days) 
using quantitative real time PCR. C3 mRNA expression was increased by 1.2 fold at pre-
symptomatic, 1.6 fold at onset, 1.6 fold at mid-symptomatic and 12.9 fold at end stage of disease, 
when compared with WT mice (n = 9, * P < 0.05, ** P < 0.01, *** P < 0.001; Figure 5.1A). The 
mRNA expression level of C3aR in the lumbar spinal cords of hSOD1
G93A
 mice also increased by 
1.4 fold, 5.2 fold and 34.0 fold at onset, mid-symptomatic and end stage respectively, when 
compared to WT mice (n=9, * P < 0.05 and *** P < 0.001; Figure 5.1B).  
 
Next we immuno-stained the lumbar spinal cords from hSOD1
G93A
 and WT mice for C3 and its 
activation product C3b with specific cellular markers for motor neurons (anti-ChAT), microglia 
(anti-Iba-1) and astrocytes (anti-GFAP). C3/C3b appeared primarily on motor neurons and 
astrocytes in hSOD1
G93A
 mice (white arrows in Figure 5.2L and 5.2R), compared to WT where 
there was little to no C3/C3b staining (Figure. 5.2A-C and Figure. 5.2G -I). Furthermore we did 
observe minimal C3/C3b staining on Iba-1 labelled microglia in hSOD
G39A
 mice but not in WT 
mice (Figure. 5.2D-F for WT mice and Figure 5.2M-O for hSOD1
G93A
 mice).  
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Figure 5.1: Increased expression of C3 and C3aR in hSOD1
G93A
 mice relative to control wild-
type mice during disease progression. (A) mRNA expression of C3 in the lumbar spinal cord of 
hSOD1
G93A
 mice relative to age-matched wild-type (WT) mice at four different ages. (B) mRNA 
expression profile of C3aR in the lumbar spinal cord of hSOD1
G93A
 mice relative to age-matched 
WT mice at four different ages. Dashed lines, baseline expression in WT controls at each time point. 
Data expressed as mean ± SEM (n = 9 mice/group; *P <0.05, ** P < 0.01, ***P <0.001, Student t 
test). PS, pre-symptomatic; OS, onset; MS, mid-symptomatic; ES, end stage. 
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Figure 5.2: Expression of C3/C3b in wild-type and hSOD1
G93A
 mice at end-stage of disease. (A) 
to (R) Double immunolabelling of C3/C3b (red) with cellular markers (green) for motor neurons 
(ChAT; (A) to (C) wild-type (WT) mice, (J) to (L) hSOD1
G93A
 mice), microglia (Iba-1; (D) to (F) 
WT mice, (M) to (O) hSOD1
G93A
 mice), and astrocytes (GFAP; (G) to (I) WT mice, (P) to (R) for 
hSOD1
G93A
 mice) in the ventral lumbar spinal cord of WT and hSOD1
G93A
 mice at end-stage of 
disease. There was minimal expression of C3/C3b in WT (A, D and G) with marked increase in 
hSOD1
G93A
 mice (J, M and P). In hSOD1
G93A
 mice, C3/C3b was co-localised with ChAT-positive 
motor neurons (white arrows in L). There was little to no co-localisation of C3/C3b with Iba-1 
positive microglia (O), and strong co-localisation with GFAP-labelled astrocytes (white arrows in 
R). Scale bars for all panels = 20 μM. 
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5.2.2 C3aR is localised to motor neurons and astrocytes with minimal localisation to microglia 
in hSOD1
G93A
 mice 
We also aimed to determine the cellular localisation of C3aR that has contributed to the increased 
expression seen in hSOD1
G93A
 mice. To achieve this, we performed immuno-labelling for C3aR on 
lumbar spinal cord sections from hSOD1
G93A
 and WT mice. These sections were immuno-stained 
for C3aR with specific cellular markers to identify motor neurons (anti-ChAT), microglia (anti-Iba-
1) and astrocytes (anti-GFAP).  
 
In WT mice C3aR staining was observed on lumbar motor neurons (Figure 5.3A). C3aR-stained 
cells were readily identified as motor neurons due to their large size, location and distinctive 
morphology (Banks et al., 2005). This was confirmed by double labelling with the motor neuron 
marker ChAT (white arrow in Figure 5.3C). Next, we examined if C3aR immuno-staining was 
present on surrounding microglia and astrocytes in sections of WT lumbar spinal cords. We 
observed no co-localization of C3aR to Iba-1 positive microglia (Figure 5.3D and 5.3F) and GFAP-
positive astrocytes (Figure 5.3G to 5.3I) in WT mice. Following this demonstration of C3aR 
immuno-labelling in WT lumbar spinal cord, we then investigated C3aR cellular localisation in 
hSOD1
G93A
 mice. C3aR was also expressed on the few remaining motor neurons seen at the end-
stage of disease (white arrow in Figure 5.3L). In hSOD1
G93A
 mice, C3aR appeared primarily on 
GFAP-positive astrocytes (white arrow in Figure 5.3R) with no observable C3aR staining on Iba-1 
positive microglia in hSOD
G39A
 mice (Figure 5.3M-O). 
 
5.2.3 hSOD1
G93A
 mice lacking C3aR have shortened survival, poorer motor performance and 
faster disease progression when compared to hSOD1
G93A
 mice 
Given our findings of strong up-regulation of C3aR, and its ligand precursor C3, in hSOD1
G93A
 
mice, we next sought to determine the role of this potential increased C3aR-activation in these mice 
by generating hSOD1
G93A
 mice lacking C3aR. Interestingly, in stark contrast to hSOD1
G93A
 mice 
lacking CD88, an absence of C3aR in hSOD1
G93A
 mice (hSOD1
G93A
 x C3aR
-/-
) showed shortened 
survival when compared to hSOD1
G93A
 mice (mean end stage of disease, hSOD1
G93A
 = 167.2 ± 2.2 
days and hSOD1
G93A
 x C3aR
-/-
 = 158.2 ± 1.7 days, n = 24, P < 0.01; Figure 5.4A). Concomitant 
with this, there was a decrease in weight of hSOD1
G93A
 x C3aR
-/-
 mice when compared to 
hSOD1
G93A
 mice at 56 days of age (n = 12, * P < 0.05, + P < 0.01, # P < 0.001, Figure 5.4B). At 
77 days hSOD1
G93A
 x C3aR
-/-
 mice also showed a significant reduction in hind-limb grip strength 
when compared to hSOD1
G93A
 mice (n = 12, * P < 0.05, + P < 0.01, # P < 0.001, Figure 5.4C). 
Absence of C3aR in hSOD1
G93A
 mice also significantly accelerated the disease progression as the 
64 
 
age at which it reached 50 and 100% decline in maximal grip strength was faster in hSOD1
G93A
 x 
C3aR
-/-
 when compared to hSOD1
G93A
 mice (n = 12, * P < 0.05, *** P < 0.001, Figure 5.4D). 
 
 
Figure 5.3: Expression of C3aR in wild-type and hSOD1
G93A
 mice at end-stage of disease. (A) to 
(R) Double immunolabelling of C3aR (red) with cellular markers (green) for motor neurons 
(ChAT; (A) to (C) wild-type (WT) mice, (J) to (L) hSOD1
G93A
 mice), microglia (Iba-1; (D) to (F) 
WT mice, (M) to (O) hSOD1
G93A
 mice), and astrocytes (GFAP; (G) to (I) WT mice, (P) to (R) for 
hSOD1
G93A
 mice) in the ventral lumbar spinal cord of WT and hSOD1
G93A
 mice at end-stage of 
disease. C3aR was mainly co-localised with ChAT-positive motor neurons in the WT mice (C, white 
arrow) with minimal co-localisation with Iba-1 labelled microglia and GFAP positive astrocytes (F 
and I). In hSOD1
G93A
 mice, C3aR immunolabelling was evident on ChAT positive motor neurons 
and GFAP positive astrocytes (L and R, white arrows). Scale bars for all panels = 20 μM. 
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Figure 5.4: hSOD1
G93A
 mice lacking C3aR have shortened survival, poorer motor performance 
and faster disease progression when compared to hSOD1
G93A
 mice. A shows a Kaplan-Meier plot 
of ages (in days) in which hSOD1
G93A
 mice with normal (C3aR
+/+
, orange line) or fully deleted 
(C3aR
-/-
, green line) C3aR reached end-stage of disease (complete hind-limb paralysis and an 
inability to right itself once placed on its back; n = 24, P < 0.01, log-rank test). hSOD1
G93A
 mice 
lacking C3aR (hSOD1
G93A
 x C3aR
-/-
) showed significant reduction in survival time relative to 
hSOD1
G93A
 mice. B shows significant reduction in weight of hSOD1
G93A
 x C3aR
-/-
 mice when 
compared to hSOD1
G93A
 mice at 56 days of age (arrows, n = 12, * P<0.05, + P<0.01, # P<0.001, 
Student t-test). C shows significant decrease in hind-limb grip strength for hSOD1
G93A
 x C3aR
-/-
 
mice versus hSOD1
G93A
 mice at 42 days of age initially and then from 77 days of age onwards (n = 
12, * P<0.05, + P<0.01, # P<0.001, Student t-test). D shows faster disease progression 
(determined by age at which maximal grip strength decline at 25, 50, 75 and 100%) in hSOD1
G93A
 x 
C3aR
-/-
 mice (green bar) when compared with hSOD1
G93A
 mice (orange bar) at 50 and 100% 
decline in maximal grip strength (n = 12, * P < 0.05, *** P < 0.001, Student t-test). hSOD1
G93A 
mice lacking C3a signaling via C3aR shows a significantly shortened in survival, reduction in 
weight, worsened hind-limb grip strength and faster disease progression, demonstrating a 
neuroprotective role for C3a in this mutant ALS mouse model. Data expressed as mean ± SEM.  
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5.2.4 hSOD1
G93A
 mice lacking C3aR have increased astrocytes and microglia mRNA levels but 
decreased monocyte mRNA levels, when compared to hSOD1
G93A
 mice throughout disease 
progression. 
One of the known actions of C3aR activation is to induce pro-inflammatory functions such as 
chemotaxis and activation of glial cells. Therefore to elucidate the mechanism of C3aR in the 
disease progression of ALS, we investigated whether the absence of C3aR in hSOD1
G93A
 mice had 
any effect on astrocytosis and microgliosis in the lumbar spinal cord. mRNA expression levels of 
GFAP (marker of astrocytes), Iba-1 (marker of both resident microglia and infiltrating 
monocyte/macrophages), Entpd1 (CD39; predominant marker of resident microglia) and Ly6C 
(predominant marker of early infiltrating monocyte/macrophages) were measured in the lumbar 
spinal cord of hSOD1
G93A
 mice and hSOD1
G93A
 x C3aR
-/-
 mice at mid-symptomatic and end-stage 
of disease progression using quantitative real time PCR. 
 
GFAP transcripts were significantly increased in hSOD1
G93A
 x C3aR
-/-
 by 1.3 fold at end-stage of 
disease when compared to hSOD1
G93A
 mice (n = 6, * P < 0.05; Figure 5.5A). Iba-1 transcripts 
were not changed in hSOD1
G93A
 x C3aR
-/- 
mice at mid-symptomatic and end-stage of disease when 
compared to hSOD1
G93A
 mice (n = 6, P > 0.05; Figure 5.5B). Entpd1 mRNA expression 
significantly increased in hSOD1
G93A
 x C3aR
-/-
 mice by 2.2 fold at mid-symptomatic stage of 
disease when compared to hSOD1
G93A
 mice (n = 6, *** P < 0.001; Figure 5.5C). However Ly6C 
mRNA was decreased at mid-symptomatic stage 0.64 fold when compared to hSOD1
G93A
 mice (n = 
6, ** P < 0.01; Figure 5.5D). 
 
5.2.5 No change in cytokine tumour necrosis factor α and interleukin-1β mRNA levels in 
hSOD1
G93A
 mice lacking C3aR when compared to hSOD1
G93A
 mice throughout disease 
progression. 
Activation of C3aR is also known to induce synthesis of cytokines to modulate inflammatory 
processes in some cell types (Takabayashi et al., 1996, Takabayashi et al., 1998). Hence we 
investigated whether the absence of C3aR in hSOD1
G93A
 mice had any effect on the levels of the 
keystone cytokine TNFα and IL-1β in the lumbar spinal cord. mRNA expression of TNFα and IL-
1β were measured in the lumbar spinal cord of hSOD1G93A mice and hSOD1G93A x C3aR-/- mice at 
mid-symptomatic and end-stage of disease progression using quantitative real time PCR. TNFα and 
IL-1β transcripts were not significantly different in hSOD1G93A x C3aR-/- mice when compared to 
hSOD1
G93A
 mice at mid-symptomatic and end-stage of disease (n = 6, P > 0.05; Figure 5.6A and 
5.6B).  
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Figure 5.5: hSOD1
G93A
 mice lacking C3aR have increased astrocytes and microglia mRNA levels 
while decreased monocytes mRNA levels when compared with hSOD1
G93A
 mice. (A) to (D) mRNA 
expressions of GFAP (astrocytes, A), Iba-1 (microglia/monocyte, B), Entpd1 (CD39; microglia, C) 
and Ly6C (monocyte, D) in lumbar spinal cord of hSOD1
G93A
 mice relative to age-matched 
hSOD1
G93A 
 mice lacking C3aR (hSOD1
G93A
 x C3aR
-/-
) at mid-symptomatic and end-stage of 
disease progression. Data expressed as mean ± SEM (n = 6 mice/group; *P <0.05, **P <0.01, 
***P <0.001, Student t test). MS (P130), mid-symptomatic - 130 days postnatal; ES (P175), end-
stage - 175 days postnatal. 
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Figure 5.6: There is no change in cytokine tumour necrosis factor α and interleukin-1β mRNA 
levels in hSOD1
G93A
 mice lacking C3aR when compared with hSOD1
G93A
 mice. (A) mRNA 
expression of tumour necrosis factor α (TNFα) in the lumbar spinal cord of hSOD1G93A mice 
relative to age-matched hSOD1
G93A 
mice lacking C3aR (hSOD1
G93A
 x C3aR
-/-
) at mid-symptomatic 
and end-stage of disease progression. (B) mRNA expression of interleukin-1β (IL-1β) in the lumbar 
spinal cord of hSOD1
G93A
 mice relative to age-matched hSOD1
G93A
 x C3aR
-/-
 mice at mid-
symptomatic and end-stage of disease progression. Data expressed as mean ± SEM (n = 6 
mice/group; P > 0.05, Student t test). MS (P130), mid-symptomatic - 130 days postnatal; ES 
(P175), end-stage - 175 days postnatal.  
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5.3 DISCUSSION 
We have previously shown that dysregulation and over-activation of complement system may be 
involved in promoting disease progression in ALS. However, deletion of C1q, C3 and C4 in hSOD1 
transgenic mouse models did not show any beneficial effects on the disease progression of ALS, 
which indicates that blocking upstream complement activation pathways does not contribute to ALS 
mice neurotoxicity (Chiu et al., 2009, Lobsiger et al., 2013). This introduces the possibility that 
downstream complement factors (C3 and C5) potentially generated by the fourth “extrinsic 
pathway”, may play a role in the disease progression of ALS. While C5a-CD88 signalling has 
clearly shown to play a pathogenic role in the disease progression of ALS in multiple rodent models 
as shown in chapter 4 (Woodruff et al., 2008a, Woodruff et al., 2014), the role of complement 
peptide C3a has never been examined in the disease progression of ALS due to a lack of selective 
and CNS permeable C3aR inhibitors (Mathieu et al., 2005, Proctor et al., 2004). Given this, we 
utilised hSOD1
G93A
 x C3aR
-/-
 mice to elucidate the function of C3aR in the disease progression of 
ALS.  
 
The present study demonstrates that the central component of complement system C3 and its 
receptor C3aR are markedly up-regulated during the course of disease progression in hSOD1
G93A
 
mice and is expressed on motor neurons and astrocytes, but surprisingly not microglia. Inhibition of 
C3aR-signalling using hSOD1
G93A
 x C3aR
-/-
 mice resulted in shortened survival, reduced body 
weight, worsened hind-limb grip strength and ultimately accelerated disease progression. 
Furthermore, we showed that hSOD1
G93A
 x C3aR
-/-
 mice also had up-regulation of astrocytes and 
resident microglia mRNA levels, while reduction in monocyte mRNA levels when compared to 
hSOD1
G93A
 mice. Taken together these results indicate that C3aR activation in hSOD1
G93A
 mice 
may play a neuroprotective role in the disease progression of ALS. 
 
5.3.1 C3 is expressed by wild-type and hSOD1
G93A
 motor neurons and is increased during 
disease progression 
C3, the central component of complement system and the precursor of C3a and C3b is expressed by 
motor neurons in both the WT and hSOD1
G93A
 mice. This suggests that motor neurons are a major 
source of complement activation in this tissue. Previously we have shown that C3b is increased in 
hSOD1
G93A
 mice and expressed on motor neurons when compared to WT (Lee et al., 2013). This 
may suggest that stressed and dying motor neurons generate their own C3b where it could assist in 
the removal of dying motor neurons via opsonisation during disease progression in hSOD1
G93A
 
mice, similar to synaptic pruning in nervous system development (Stevens et al., 2007). We also 
showed that C5, the downstream complement factor of C3 is generated in the motor neurons of 
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hSOD1
G93A
 mice. Additionally, our previous studies showed that cortical neurons can generate their 
own C5a to act in an autocrine fashion by binding to CD88 present on these neurons (Pavlovski et 
al., 2012). This suggests that motor neurons could also be capable of generating their own 
complement peptides, which can directly cause neuronal cell death in this mouse model of ALS. 
Like C5a-CD88 signalling in motor neurons, the consequence of C3a-C3aR signalling in WT motor 
neurons is not yet fully understood and will need further investigation.  
 
5.3.2 C3aR is expressed on motor neurons and up-regulated during disease progression in 
hSOD1
G93A
 mice 
The present study provided evidence for pathophysiological role of C3aR in hSOD1
G93A
 mice. 
Specifically, a significant up-regulation in C3aR mRNA level was observed at onset, mid-
symptomatic and end-stage of disease in hSOD1
G93A
 mice. Unlike CD88, where it has been 
extensively studied to show that CD88 activation could actively contribute to neurodegeneration in 
various neurodegenerative diseases, the function of C3aR has received limited attention due to its 
complex, multifarious and context - dependent role of C3a (Klos et al., 2009). Interestingly, recent 
studies have proposed two contradicting functions of C3a-C3aR signalling in neurodegeneration 
where some showed pro-inflammatory and anti-inflammatory functions (Jacob et al., 2010, 
Yanamadala and Friedlander, 2010).  
 
In addition to an increase in C3aR in hSOD1
G93A
 mice, the current study observed localization of 
C3aR on motor neurons in both the WT and hSOD1
G93A
 mice. The fact that C3aR was found on 
WT motor neurons suggests that C3aR may play a non-inflammatory role in the homeostasis of 
motor neuronal viability. Indeed, other studies have shown C3aR is also expressed in other neurons 
within the brains of the WT adult mice including hippocampal and cortical neurons (Davoust et al., 
1999). Local expression of C3aR in motor neurons could be explained in terms of its involvement 
in increasing neuronal motility and migration during neurogenesis (Benard et al., 2008). Further 
evidence to support this notion is a study which utilised C3 and C3aR deficient mice, where these 
mice developed impairment of neurogenesis indicating that C3a – C3aR signalling is essential in 
neuroblast migration (Rahpeymai et al., 2006).  It was also shown that C3a – C3aR signalling can 
induce neural progenitor cells in the CNS to differentiate, mature and migrate (Shinjyo et al., 2009).  
 
Although there is substantial evidence for the role of C3a – C3aR signalling in the early 
development of cerebellar neurons there is no evidence to date reported in adult motor neurons. 
Hence, future studies could be developed using cultured motor neuron cells to elucidate the 
physiological significance of C3a receptor presence in motor neurons. Specifically motor neurons 
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could be exposed to stress and treated with C3a to assess the role that C3a – C3aR signalling may 
play in maintaining motor neuronal survival. However, based on the current evidence mentioned 
above, it is postulated that the expression of C3aR on motor neurons serves to provide homeostasis 
for motor neuronal viability, neurogenesis and migration, as a protective mechanism under normal 
physiology condition or a repair mechanism after CNS insult. 
 
5.3.3 C3aR is expressed on proliferating astrocytes in hSOD1
G93A
 mice 
It has become increasingly clear that non-neuronal neighbouring cells (astrocytes and microglia) 
can release toxic signals that can exacerbate motor neuron death in animal models of ALS 
(Kreutzberg, 1996, Nagai et al., 2007). The present study showed up regulation of C3aR on 
proliferating astrocytes, but minimal expression on activated microglia in hSOD1
G93A
 mice. The 
strong co-localisation of C3aR with proliferating astrocytes during disease progression of ALS 
suggests that the presence of C3aR on astrocytes is triggered by injury/insult from the disease. This 
is postulated to be a protective mechanism for the survival of adjacent motor neurons, as it has been 
previously found that C3a exerts beneficial effects against N-methyl-D-aspartate (NMDA)-induced 
neuronal death in mixed cultures of neurons and astrocytes but not in pure neuronal cultures (van 
Beek et al., 2001). Since the neuroprotective effect could only be seen in the presence of astrocytes, 
it suggests that C3a-C3aR signalling in astrocytes could be involved in modulating neuronal 
glutamate signalling and ultimately providing beneficial effects against NMDA toxicity. This also 
provides evidence of C3a-C3aR signalling on proliferating astrocytes in hSOD1
G93A
 mice protecting 
motor neurons against glutamate excitoxicity, as NMDA receptors are known to regulate Ca
2+
 
influx into neurons and thus mediate glutamate excitoxicity (Yanamadala and Friedlander, 2010).  
 
Despite the above evidence for C3a-C3aR signalling being neuroprotective, other studies have also 
shown that C3a-C3aR signalling in astrocytes could have a pathogenic role in the disease 
progression of ALS. It was found that co-stimulation of rat primary astrocytes with C3a/IL-1β 
resulted in a synergistic effect where nerve growth factor (NGF) production was increased (Jauneau 
et al., 2006). Although NGF is a neurotrophic factor which plays an essential role in maintaining the 
function and survival of neurons (Hetman and Xia, 2000, Yuen and Mobley, 1996), a study using 
hSOD1
G93A
 mice and cultured reactive astrocytes showed that NGF induced motor neuron death 
due to the activation of p75
NTR
 receptor pathway in response to pathological conditions (Pehar et 
al., 2004, Domeniconi et al., 2007).  
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Collectively, these studies suggest that C3a-C3aR signalling in hSOD1
G93A
 mice could have both 
pro- and anti-inflammatory functions, indicating that the equilibrium between these two functions 
will be important factor when looking at the role of C3aR in disease progression of ALS.  
 
5.3.4 Absence of C3a-C3aR signalling in hSOD1
G93A
 mice worsens hind-limb grip strength, 
lowers body weight, accelerates disease progression and shortens survival time. 
In the present study we used hSOD1
G93A
 x C3aR
-/-
 mice to elucidate the role of C3a-C3aR 
signalling in the disease progression of ALS. We report for the first time that hSOD1
G93A
 x C3aR
-/-
 
mice have shortened survival time, worsened hind-limb grip strength, reduced body weight and 
accelerated disease progression when compared to hSOD1
G93A
 mice, suggesting that C3aR plays a 
neuroprotective role in these mice. This is in agreement with previous studies where they showed 
that C3a might provide a protective role in the central nervous system (CNS). Transgenic mice 
overexpressing C3a in astrocytes were significantly resistant to mortality induced by endotoxic 
shock compared with WT and C3aR deficient mice (Boos et al., 2005). Another study using mouse 
model of Alzheimer’s disease showed that knocking out amyloid precursor protein (the protein that 
forms the plaque in the disease) resulted in neuroprotection, with elevated levels of C3a in the 
cerebrospinal fluid (Zhou et al., 2008). Taken together these results suggest that C3a-C3aR 
signalling in the context of CNS provides neuroprotective role, hence neuroprotection in the disease 
progression of ALS.  
 
5.3.5 Increased astrocytes/microglia mRNA levels while reduced monocyte mRNA levels in 
hSOD1
G93A
 mice lacking C3aR 
As mentioned previously, there is increasing evidence that motor neuron death in ALS animal 
models is exacerbated by toxic signals emanating from non-neuronal neighbouring cells (astrocytes 
and microglia) via an inflammatory response that accelerates disease progression (Nagai et al., 
2007, Kreutzberg, 1996). We showed strong co-localisation of C3aR to astrocytes and minimal co-
localisation of C3aR to microglia in hSOD1
G93A
 transgenic mice. Hence to elucidate the mechanism 
of C3a-C3aR signalling in astrocytes in the disease progression of ALS, we investigated whether 
the absence of C3aR in hSOD1
G93A
 mice had any effect on astrocytosis and microgliosis. We 
showed that there was a significant increase in astrocytes and microglia mRNA levels (GFAP, 
Entpd1) in hSOD1
G93A
 x C3aR
-/-
 mice when compared to hSOD1
G93A
 mice at end-stage and mid-
symptomatic stage of disease respectively, while there was a significant reduction in monocyte 
mRNA levels (Ly6C) in hSOD1
G93A
 x C3aR
-/-
 mice at mid-symptomatic stage of disease. This 
suggests that at least some of the detrimental effects seen with C3aR inhibition could be due to the 
lack of C3a-mediated reduction of astrocytes and microglia in this mouse model of ALS. This 
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supports many studies where they have shown non-neuronal neighbouring cells (astrocytes and 
microglia) release toxic factors that are detrimental to motor neuron survival (Julien, 2007, Henkel 
et al., 2009, Fritz et al., 2013, Rojas et al., 2014). Although we showed increased microglia mRNA 
levels (Entpd1) in hSOD1
G93A
 x C3aR
-/-
 mice when compared to hSOD1
G93A
 mice at mid-
symptomatic stage, we also showed a decrease in monocyte mRNA level (Ly6C) in hSOD1
G93A
 x 
C3aR
-/-
 mice at the same age. This was an interesting result as it contradicts recent studies where 
they showed decreasing infiltration of Ly6C-positive monocytes to the spinal cord attenuated motor 
neuron death and slowed disease progression in hSOD1
G93A 
mice (Butovsky et al., 2012). However, 
this supports other studies where they showed that resident microglia but not peripheral monocytes 
are major participants in ALS spinal cord innate immune activation (Chiu et al., 2013).  
 
The activation states of microglia and astrocytes with respect to protection versus toxicity cannot be 
inferred solely from their morphology markers (GFAP, Iba-1, Entpd1 and Ly6C) (Beers et al., 
2008). Hence we looked at mRNA expression of pro-inflammatory cytokine such as TNFα and IL-
1β, which is known to be functional markers of activation (Beers et al., 2008). Interestingly, we 
showed that there was no difference between hSOD1
G93A
 x C3aR
-/-
 mice and hSOD1
G93A
 mice for 
TNFα and IL-1β. This suggests that absence of C3a-C3aR signalling in astrocytes of hSOD1G93A 
mice is worsening the disease outcome through other mechanism rather than increasing 
inflammation. For example, astrocytes are well known to respond to inflammation and injury of the 
CNS through the release of neutrophic factors such as glial cell line-derived neurotrophic factor 
(GDNF) (Llado et al., 2004, Appel et al., 1997), brain-derived nerurotrophic factor (BDNF) 
(Dougherty et al., 2000) and neurotrophin-3 (NT-3) (Dougherty et al., 2000). These factors are 
known to support motor neuronal survival (Koliatsos et al., 1993, Rakowicz et al., 2002, Whitehead 
et al., 2005, Gibbons et al., 2005). In the case for GDNF, it is released from astrocytes when such 
cells are exposed to inflammatory cytokines TNF-α, lipopolysaccharides and interferon-γ (Appel et 
al., 1997, Llado et al., 2004). Not only does GDNF promote motor neuron survival (Zhao et al., 
2004), but can provide protection from apoptosis by inhibiting caspase-3 (Yu et al., 2007).  
 
As mentioned, astrocytes have also been shown to increase its release of BDNF and NT-3 upon 
stimulus of spinal cord injury (Dougherty et al., 2000). BDNF prevents motor neuronal 
degeneration and induces axonal growth (Kishino et al., 1997). While the role of NT-3 in protecting 
motor neurons has not been investigated, other studies have found that it does play a protective role 
in sensory neurons (Tessarollo et al., 1994).  In support of these ideas, we have recently shown that 
C3a can stimulate up-regulation of BDNF and NT-3 mRNA levels from astrocytes (unpublished 
data). Hence it is plausible that C3a-C3aR signalling in astrocytes in hSOD1
G93A
 mice can release 
74 
 
GDNF, BDNF and NT-3 to dampen the detrimental effects of astrocytes and protect against motor 
neuronal death. 
 
5.4 CONCLUSION 
In summary, the present study has demonstrated the up-regulation of central component C3 and its 
receptor C3aR in hSOD1
G93A
 mice, and the increased expression of C3 and C3aR in end-stage 
hSOD1
G93A
 mice appears to be due to increased astroglial C3 and C3aR expression. We also 
showed for the first time that inhibition of C3aR using hSOD1
G93A
 x C3aR
-/-
 mice significantly 
reduced hind-limb grip strength and body weight. It also accelerated disease progression and 
shortened survival, suggesting that C3a-C3aR signalling in these animals plays a neuroprotective 
role and protects motor neurons from dying. Expression of astrocytes and microglia mRNA level 
was increased while monocyte mRNA level was decreased in hSOD1
G93A
 x C3aR
-/-
 mice. 
Interestingly cytokines (TNFα and IL-1β) transcripts were not changed between hSOD1G93A x 
C3aR
-/-
 mice and hSOD1
G93A
 mice. Taken together these results indicate that inhibition of C3aR 
significantly exacerbates disease progression by increasing levels of astrocytes and microglia but 
not via modulation of inflammatory cytokines. This also opens the new window of opportunity as 
lack of C3a-C3aR signalling in astrocytes worsens the disease outcome through other mechanisms 
rather than increasing inflammation. Specifically, whilst our previous studies suggest that inhibiting 
the pro-inflammatory C5 activation fragment, C5a, which is central to, and generated by, all 
complement pathways, may be a novel therapeutic strategy to treat ALS, our data shows C3aR 
agonism offers a novel alternate or complementary therapeutic strategy to treat ALS. 
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CHAPTER 6 
“Conclusion and future direction” 
 
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is the most common 
form of motor neuron disease. It is a debilitating, devastating late onset neurodegenerative disorder 
that is characterized by the progressive death of upper and lower α-motor neurons within the central 
nervous system (CNS) (Bruijn et al., 2004). Over 50% of ALS patients die within 3-5 years after 
diagnosis and there is no cure for this disease. Our limited understanding of the cellular and 
molecular mechanisms that leads to the motor neuron death restricts the development of treatments 
for the disease. While the pathogenesis of ALS is still unclear, there is persuasive evidence that 
complement factors are involved in promoting the progression of disease. Therefore the aim of this 
thesis was to investigate the role of complement system in the disease progression of ALS using 
hSOD1
G93A
 mice as an animal model. The key findings of the present study are: 1) dysregulation of 
complement including up-regulation of CD88 and C3aR in hSOD1
G93A
 mice; 2) confirmation that 
CD88 has a pathogenic role in hSOD1
G93A
 mice and 3) identification of C3aR as playing a 
neuroprotective role in hSOD1
G93A
 mice. 
 
In chapter 3 I demonstrated up-regulation of components of classical pathway (C1qB and C4), 
alternative pathway (factor B) and the central component common to all pathways (C3), together 
with decreased levels of complement regulators (CD55 and CD59a). This suggests that complement 
activation and/or its dysregulation may play an important role in motor neuron loss and ultimately 
in progression of ALS. Additionally this study also showed increased C1q and C3b immuno-
labelling in hSOD1
G39A
 mice and expression on motor neurons and microglia compared to wild-
type. This may suggest that up-regulation of these components could assist in the removal of dying 
motor neurons via opsonisation, during disease progression in hSOD1
G93A
 mice, similar to synaptic 
pruning during development (Stevens et al., 2007). Collectively, our data from chapter 3 added 
further support to the notion that complement activation may play an important role in accelerating 
motor neuron loss and ultimately in progression of ALS.  
 
Despite these findings, recent studies have shown that deletion of upstream complement component 
C1q, C3 and C4 in hSOD1 transgenic mouse models did not show any beneficial effects on the 
disease progression of ALS (Chiu et al., 2009, Lobsiger et al., 2013). This is a somewhat surprising 
result, given the findings presented in Chapter 3, and that of previous published work showing 
strong activation of complement in ALS. These recent complement knockout studies indicate that 
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blocking upstream complement activation pathways do not contribute to ALS mice neurotoxicity. 
In addition to these opsonins (C1q and C3/C3b), cleavage products of C3 and C5 (C3a and C5a) 
and their receptors (C3aR and CD88) are also critical for mediating and executing the majority of 
complement-mediated inflammatory response. Hence it also introduces the new possibility that 
downstream complement factors, potentially generated by the fourth “extrinsic pathway”, may play 
a role in the disease progression of ALS 
 
In support of this hypothesis, my research also showed a significant increase in CD88 protein in 
hSOD1
G93A
 mice (Chapter 3). This supports other studies where they have shown up-regulation of 
CD88 in numerous neurodegenerative diseases including ALS, which makes it plausible to propose 
that downstream complement C5a-CD88 signalling may have a direct pathogenic role in the disease 
progression of ALS (Lee et al., 2013). Furthermore I demonstrated that inhibition of CD88 using 
oral administration of a specific CD88 antagonist, PMX205, significantly improved hind-limb grip 
strength, slowed disease progression and extended survival. This was also confirmed using 
hSOD1
G93A
 mice lacking CD88 (hSOD1
G93A
 x CD88
-/-
), suggesting that CD88 activation 
contributes to motor neuron death seen in this model of ALS. I also showed in Chapter 4 that 
hSOD1
G93A
 x CD88
-/-
 mice had reduced expression of microglia and monocyte markers, and 
cytokine (TNFα and IL-1β) mRNA transcripts. This suggests that the increased CD88 expressed on 
microglia in hSOD1
G93A
 mice may have many pathogenic functions including 
chemotaxis/proliferation of microglia, recruitment of inflammatory monocytes, and ultimately pro-
inflammatory cytokine induction that may propagate the disease progression of ALS. Taken 
together these results indicate that CD88 has a pathogenic (pro-inflammatory) role and inhibition of 
CD88 can significantly attenuate disease progression by reducing inflammation that may accelerate 
motor neuron death and contribute to the pathology in hSOD1
G93A
 mice. One caveat with this 
hypothesis is that this study to date has only looked at the mRNA level, and now needs to be 
extended to the protein levels for the markers microglia, monocyte and cytokine using western 
blotting, immunohistochemistry and ELISA.  
 
Another interesting finding I obtained from Chapter 3, was that C5, the precursor of C5a, is 
expressed predominantly by motor neurons, suggesting that diseased motor neurons could be a 
major source of C5a generation during disease progression. This local complement “self-signalling” 
in the CNS might therefore contribute to motor neuron death in hSOD1
G93A
 mice directly as shown 
previously by our group for cortical neurons (Pavlovski et al., 2012). Alternatively, locally 
generated C5a by injured motor neurons could act indirectly by acting as a chemoattractant and 
mitogen for resident microglia, infiltrating monocytes, resulting in their activation to induce 
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cytokine release from these cells which will ultimately contribute to motor neuron death. To further 
understand the relative contribution of CD88 expression in the CNS and circulating white blood 
cells in relation to ALS progression, we are proposing to utilise the bone-marrow (BM) chimeric 
studies where we can generate a number of BM chimeric mice with CD88 deficiency in CNS or 
peripheral blood to elucidate whether the benefits of CD88 ablation in disease progression of ALS 
are partially or solely mediated via altered peripheral immune cell responses in hSOD1
G93A
 mice. 
This will help us to pin point the mechanism by which CD88 activation worsens disease pathology 
in ALS and assist in future therapeutic strategies targeting complement activation. These BM 
chimeric studies are currently underway in our laboratory. 
 
By contrast to C5a-CD88 signalling where it has clearly been shown to play a pathogenic role in the 
disease progression of ALS in multiple rodent models (Woodruff et al., 2008a, Woodruff et al., 
2014), the role of complement peptide C3a has never been examined in the disease progression of 
ALS, possibly due to a lack of selective and CNS permeable C3aR inhibitors (Mathieu et al., 2005, 
Proctor et al., 2004). Given the lack of data for a role of C3a-C3aR signalling in ALS, we utilised 
hSOD1
G93A
 mice lacking C3aR (hSOD1
G93A
 x C3aR
-/-
) to elucidate the function of C3aR in the 
disease progression of ALS. In addition to an up-regulation of the central component of 
complement system C3, we also showed that its receptor C3aR is up-regulated during the course of 
disease progression in hSOD1
G93A
 mice and is expressed on motor neurons and astrocytes, but 
interestingly completely absent on microglia. Inhibition of C3a-C3aR signalling using hSOD1
G93A
 x 
C3aR
-/-
 mice resulted in shortened survival, reduced body weight, worsened hind-limb grip strength 
and ultimately accelerated disease progression. Taken together these results indicate that C3aR 
activation in hSOD1
G93A
 mice may play a neuroprotective role in the disease progression of ALS. 
 
Like C5a-CD88 signalling, the knowledge about the cellular and molecular mechanism of C3a-
C3aR signalling in the disease progression of ALS is very limited. Hence in chapter 5, I tried to 
dissect out some of the mechanisms that C3a-C3aR signalling could contribute to its 
neuroprotective role in the disease progression of ALS. We showed that hSOD1
G93A
 x C3aR
-/-
 mice 
had up-regulation of astrocytes and resident microglia markers, but reduction in infiltrating 
monocyte markers when compared to hSOD1
G93A
 mice. We also showed that there was no 
difference in cytokines (TNFα and IL-1β) levels between hSOD1G93A x C3aR-/- mice and 
hSOD1
G93A
 mice. Taken together these results indicate that C3aR activation on astrocytes in 
hSOD1
G93A
 mice may play a role in slowing down proliferation of astrocyte and microglia which 
may reduce the toxic signals (other than cytokine) emanating from these cells and ultimately 
slowing down the disease progression of ALS (Re et al., 2014, Phatnani et al., 2013). However, as 
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mentioned above, this study needs to be extended to the protein levels for the markers microglia, 
monocyte and cytokine using western blotting, immunohistochemistry and ELISA. It is also 
possible that C3a could exert its beneficial effects by modulating neuronal glutamate signalling and 
providing protection against N-methyl-D-aspartate toxicity seen in hSOD1
G93A
 mice. Previous 
studies have demonstrated as similar scenario whereby C3a-induced production of cytokine such as 
interleukin-6 and growth factors such as nerve growth factor (NGF) by these glial cells were found 
to display a neuroprotective effect against glutamate-mediated neuronal cell death (Ali et al., 2000, 
Park et al., 2012, Carlson et al., 1999, El Idrissi and Trenkner, 1999, Kume et al., 2000). In support 
of this idea, we have recently shown that C3a can stimulate up-regulation of brain-derived 
neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) mRNA levels from astrocytes (unpublished 
data). Hence it is plausible that C3a-C3aR signalling in astrocytes in hSOD1
G93A
 mice can release 
NGF, glial-derived neurotrophic factor, BDNF and NT-3 to dampen the glutamate excitoxicity and 
protect against motor neuronal death. These ideas are currently being pursued in our laboratory. 
 
Taken together these results of this thesis indicate that the role of complement activation in the 
disease progression of ALS is complex and can be viewed as a double-edge sword (similar to 
inflammation in general), which is either detrimental or beneficial depending on which complement 
pathway (C5a-CD88 or C3a-C3aR signalling pathway) is dominant. This emphasises the 
importance of equilibrium within the complement system as the complement peptides C3a and C5a 
generated during complement activation and their receptors C3aR and CD88 have two opposing 
roles in the progression of ALS in the hSOD1
G93A
 mouse. Hence, my results propose that 
modulating complement activation in ALS should be targeted towards downstream C5a inhibition, 
in order to avoid blocking any endogenous protective effects of upstream factors such as C3a in 
ALS progression. 
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